WO2019123250A1 - Methods and compositions for inducing an immune response against hepatitis b virus (hbv) - Google Patents

Methods and compositions for inducing an immune response against hepatitis b virus (hbv) Download PDF

Info

Publication number
WO2019123250A1
WO2019123250A1 PCT/IB2018/060257 IB2018060257W WO2019123250A1 WO 2019123250 A1 WO2019123250 A1 WO 2019123250A1 IB 2018060257 W IB2018060257 W IB 2018060257W WO 2019123250 A1 WO2019123250 A1 WO 2019123250A1
Authority
WO
WIPO (PCT)
Prior art keywords
hbv
seq
antigen
sequence
composition
Prior art date
Application number
PCT/IB2018/060257
Other languages
English (en)
French (fr)
Inventor
Daniel BODEN
Helen Horton
Jean-Marc Edmond Fernand Marie Neefs
Soumitra Roy
Jerome Hubertina Henricus Victor Custers
Roland Christian Zahn
Markus Kalla
Original Assignee
Janssen Sciences Ireland Unlimited Company
Bavarian Nordic A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SG11202005710YA priority Critical patent/SG11202005710YA/en
Priority to AU2018389786A priority patent/AU2018389786A1/en
Priority to BR112020012273-4A priority patent/BR112020012273A2/pt
Priority to EA202091516A priority patent/EA202091516A1/ru
Priority to CA3086325A priority patent/CA3086325A1/en
Priority to MX2020006471A priority patent/MX2020006471A/es
Application filed by Janssen Sciences Ireland Unlimited Company, Bavarian Nordic A/S filed Critical Janssen Sciences Ireland Unlimited Company
Priority to JP2020533786A priority patent/JP2021506300A/ja
Priority to CN201880089584.0A priority patent/CN111741766A/zh
Priority to EP18839618.8A priority patent/EP3727446A1/en
Priority to KR1020207020749A priority patent/KR20200100745A/ko
Publication of WO2019123250A1 publication Critical patent/WO2019123250A1/en
Priority to IL275423A priority patent/IL275423A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Definitions

  • This application contains a sequence listing, which is submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file name“688097-413 Sequence Listing” and a creation date of December 14, 2018, and having a size of 49.6 KB.
  • the sequence listing submitted via EFS-Web is part of the specification and is herein incorporated by reference in its entirety.
  • This invention relates to biotechnology. More particularly, the invention relates to methods and compositions for enhancing an immune response to Hepatitis B Virus (HBV) in a subject in need thereof.
  • HBV Hepatitis B Virus
  • Hepatitis B virus is a small 3.2-kb hepatotropic DNA virus that encodes four open reading frames and seven proteins. About two billion people are infected with HBV, and approximately 240 million people have chronic hepatitis B infection (chronic HBV), characterized by persistent virus and subvirus particles in the blood for more than 6 months (1). Persistent HBV infection leads to T-cell exhaustion in circulating and intrahepatic HBV-specific CD4+ and CD8+ T-cells through chronic stimulation of HBV- specific T-cell receptors with viral peptides and circulating antigens. As a result, T-cell polyfunctionality is decreased (i.e., decreased levels of IL-2, tumor necrosis factor (TNF)- a, IFN-g, and lack of proliferation).
  • TNF tumor necrosis factor
  • a safe and effective prophylactic vaccine against HBV infection has been available since the l980s and is the mainstay of hepatitis B prevention (3).
  • the World Health Organization recommends vaccination of all infants, and, in countries where there is low or intermediate hepatitis B endemicity, vaccination of all children and adolescents ( ⁇ 18 years of age), and of people of certain at risk population categories. Due to vaccination, worldwide infection rates have dropped dramatically. However, prophylactic vaccines do not cure established HBV infection.
  • cccDNA which plays a fundamental role as a template for viral RNAs, and thus new virions. It is thought that induced virus-specific T-cell and B-cell responses can effectively eliminate cccDNA-carrying hepatocytes.
  • Current therapies targeting the HBV polymerase suppress viremia, but offer limited effect on cccDNA that resides in the nucleus and related production of circulating antigen. The most rigorous form of a cure may be elimination of HBV cccDNA from the organism, which has neither been observed as a naturally occurring outcome nor as a result of any therapeutic intervention.
  • HBV surface antigens HBsAg
  • loss of HBsAg is a clinically credible equivalent of a cure, since disease relapse can occur only in cases of severe immunosuppression, which can then be prevented by prophylactic treatment.
  • loss of HBsAg is associated with the most stringent form of immune reconstitution against HBV.
  • pegylated interferon (peglFN)-a has proven better in comparison to nucleoside or nucleotide therapy in terms of sustained off- treatment response with a finite treatment course.
  • IFN-a is reported to exert epigenetic suppression of cccDNA in cell culture and humanized mice, which leads to reduction of virion productivity and transcripts (4).
  • this therapy is still fraught with side-effects and overall responses are rather low, in part because IFN-a has only poor modulatory influences on HBV-specific T-cells. In particular, cure rates are low ( ⁇ 10%) and toxicity is high.
  • HBV antivirals namely the HBV polymerase inhibitors entecavir and tenofovir
  • HBV polymerase inhibitors entecavir and tenofovir are effective as monotherapy in inducing viral suppression with a high genetic barrier to emergence of drug resistant mutants and consecutive prevention of liver disease progression.
  • cure of chronic hepatitis B defined by HBsAg loss or seroconversion, is rarely achieved with such HBV polymerase inhibitors. Therefore, these antivirals in theory need to be administered indefinitely to prevent reoccurrence of liver disease, similar to antiretroviral therapy for human immunodeficiency virus (HIV).
  • Therapeutic vaccination has the potential to eliminate HBV from chronically infected patients (5). Many strategies have been explored, but to date therapeutic vaccination has not proven successful.
  • An MVA vector of the application comprises a non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:
  • the HBV polymerase antigen of the MVA vectors can, for example, be capable of inducing an immune response in a mammal against at least two HBV genotypes.
  • the HBV polymerase antigen is capable of inducing a T cell response in a mammal against at least HBV genotypes B, C, and D. More preferably the HBV polymerase antigen is capable of inducing a CD 8 T cell response in a human subject against at least HBV genotypes A, B, C, and D.
  • an HBV polymerase antigen comprises the amino acid sequence of SEQ ID NO: 4.
  • the first polynucleotide sequence is at least 90% identical to SEQ ID NO: 3.
  • the first polynucleotide sequence comprises the polynucleotide sequence of SEQ ID NO: 3.
  • an MVA vector can further comprise a polynucleotide sequence encoding a signal sequence operably linked to the HBV polymerase antigen.
  • the signal sequence can, for example, comprise an amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 11.
  • the signal sequence is encoded by the polynucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 10.
  • an MVA vector further comprises a second polynucleotide sequence encoding a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2.
  • the second polynucleotide sequence is at least 90% identical to SEQ ID NO: 1.
  • the second polynucleotide sequence comprises the polynucleotide sequence of SEQ ID NO: 1.
  • compositions comprising an MVA vector of the application and a pharmaceutically acceptable carrier.
  • the methods comprise (a) administering to the human subject a first composition comprising an immunologically effective amount of an adenovirus vector comprising a non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:4; and (b) administering to the human subject a second composition comprising an immunologically effective amount of an MVA vector of the application; to thereby obtain an enhanced immune response against the HBV antigen in the human subject.
  • the HBV polymerase antigen does not have reverse transcriptase activity and RNase H activity.
  • the first composition is for priming the immune response
  • the second composition is for boosting the immune response in the subject in need thereof.
  • step (b) is conducted 1-12 weeks after step (a). In an embodiment of the application, step (b) is conducted 2-12 weeks after step (a). In an embodiment of the application, step (b) is conducted at least 1 week after step (a). In an embodiment of the application, step (b) is conducted at least 2 weeks after step (a).
  • an HBV polymerase antigen of the first composition is capable of inducing an immune response in the human subject against at least two HBV genotypes, preferably the HBV polymerase antigen is capable of inducing a T cell response in the human subject against at least HBV genotypes B, C, and D, and more preferably the HBV polymerase antigen is capable of inducing a CD8 T cell response in the human subject against at least HBV genotypes A, B, C, and D.
  • the HBV polymerase antigen of the first composition comprises the amino acid sequence of SEQ ID NO: 4.
  • polynucleotide sequence of the first composition can, for example, be at least 90% identical to SEQ ID NO: 19.
  • the first composition can, for example, be at least 90% identical to SEQ ID NO: 19.
  • polynucleotide sequence of the first composition comprises the polynucleotide sequence of SEQ ID NO: 19.
  • the nucleic acid molecule of the adenovirus vector in the first composition further comprises a second polynucleotide sequence encoding a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2.
  • the second polynucleotide sequence of the first composition can, for example, be at least 90% identical to SEQ ID NO: 17.
  • the second polynucleotide sequence of the first composition comprises the polynucleotide sequence of SEQ ID NO: 17.
  • the first and second polynucleotide sequences of the first composition encode a fusion protein comprising the truncated HBV core antigen operably linked to the HBV polymerase antigen.
  • the fusion protein of the first composition can, for example, comprise the truncated HBV core antigen operably linked to the HBV polymerase antigen via a linker.
  • the linker of the first composition can, for example, comprise the amino acid sequence of (AlaGly) n , wherein n is an integer of 2 to 5.
  • the linker is encoded by a polynucleotide sequence comprising SEQ ID NO: 14.
  • the fusion protein of the first composition comprises the amino acid sequence of SEQ ID NO: 12.
  • the enhanced immune response comprises an enhanced antibody response against the HBV antigen in the human subject.
  • the enhanced immune response can, for example, comprise an enhanced CD8+ T cell response against the HBV antigen in the human subject.
  • the enhanced immune response can, for example, comprise an enhanced CD4+ T cell response against the HBV antigen in the human subject.
  • the adenovirus vector is an rAd26 or rAd35 vector.
  • a method of enhancing an immune response in a human subject comprises (a) administering to the human subject a first composition comprising an immunologically effective amount of a first plasmid comprising a first non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO: 4 and a second plasmid comprising a second non-naturally occurring nucleic acid molecule comprising a second
  • the HBV polymerase antigen of the first composition does not have reverse transcriptase activity and RNase H activity.
  • the first composition is for priming the immune response and the second composition is for boosting the immune response.
  • step (b) is conducted 1-12 weeks after step (a). In an embodiment of the application, step (b) is conducted 2-12 weeks after step (a). In an embodiment of the application, step (b) is conducted at least 1 week after step (a). In an embodiment of the application, step (b) is conducted at least 2 weeks after step (a).
  • the HBV polymerase antigen of the first composition is capable of inducing an immune response in the human subject against at least two HBV genotypes, preferably the HBV polymerase antigen is capable of inducing a T cell response in the human subject against at least HBV genotypes B, C, and D, and more preferably the HBV polymerase antigen is capable of inducing a CD8 T cell response in the human subject against at least HBV genotypes A, B, C, and D.
  • the HBV polymerase antigen of the first composition comprises the amino acid sequence of SEQ ID NO: 4.
  • polynucleotide sequence of the first composition can, for example, be at least 90% identical to SEQ ID NO: 19.
  • the first polynucleotide sequence of the first composition comprises the polynucleotide sequence of SEQ ID NO: 19.
  • the HBV polymerase antigen of the first composition comprises the amino acid sequence of SEQ ID NO: 4.
  • the first polynucleotide sequence of the first composition is at least 90% identical to SEQ ID NO: 20.
  • the first polynucleotide sequence of the first composition can, for example, comprise SEQ ID NO: 20.
  • the nucleic acid molecule of the first plasmid of the first composition further comprises a polynucleotide sequence encoding a signal sequence operably linked to the HBV polymerase antigen of the first composition.
  • the signal sequence can, for example, comprise the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 11, preferably the signal sequence is encoded by the polynucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 10.
  • the second polynucleotide sequence of the first composition is at least 90% identical to SEQ ID NO: 18.
  • the second polynucleotide sequence of the first composition can, for example, comprise the polynucleotide sequence of SEQ ID NO: 18.
  • the first and second polynucleotide sequences of the first composition further comprise a promoter sequence, optionally one or more additional regulatory sequences, preferably the promoter sequence comprises the polynucleotide sequence of SEQ ID NO: 7, and the additional regulatory sequence is selected from the group consisting of an enhancer sequence of SEQ ID NO: 8 or SEQ ID NO: 15, and a polyadenylation signal sequence of SEQ ID NO: 16.
  • the enhanced immune response comprises an enhanced antibody response against the HBV antigen in the human subject.
  • the enhanced immune response can, for example, comprise an enhanced CD8+ T cell response against the HBV antigen in the human subject.
  • the enhanced immune response can, for example, comprise an enhanced CD4+ T cell response against the HBV antigen in the human subject.
  • FIGS. 1A-1B depict the genome and viral life cycle of hepatitis B virus
  • FIG. 1A is a diagram of the genome of hepatitis B virus (HBV); in the native virus, the polymerase protein (Pol) contains the coding sequence for the envelope proteins in a different open reading frame; the envelope proteins (pre-Sl, pre-S2, and S) are in the same open reading frame;
  • FIG. IB shows the viral life cycle of HBV;
  • FIGS. 2A-2C show the schematic representations of the expression cassettes in adenoviral and MVA vectors according to embodiments of the application;
  • FIG. 2A shows the expression cassette for a truncated HBV core antigen, which contains a CMV promoter, an intron (a fragment derived from the human ApoAI gene - GenBank accession X01038 base pairs 295 - 523, harboring the ApoAI second intron), a human immunoglobulin secretion signal, followed by a coding sequence for a truncated HBV core antigen and a SV40 polyadenylation signal;
  • FIG. 2B shows the expression cassette for a fusion protein of a truncated HBV core antigen operably linked to a HBV
  • FIG. 2C shows an expression cassette comprising a HBV core antigen operably linked to a Prl3.5 long promoter and an expression cassette comprising a HBV polymerase antigen operably linked to a PrHyb promoter;
  • FIG. 3 shows a graph of ELISPOT responses of Fl mice immunized with different combinations of HBV adenoviral vectors and HBV MVA; HBV core or polymerase peptide pools used to stimulate splenocytes isolated from the various vaccinated animal groups are indicated in black (core) and grey (pol). Poll and pol2 responses were summed; the X-axis shows the adenovector dose and the presence or absence of the MVA boost; the number of responsive T-cells are indicated on the y-axis expressed as spot forming cells (SFC) per 10 6 splenocytes;
  • SFC spot forming cells
  • FIG. 4 shows a graph of intracellular cytokine staining (ICS) responses of Fl mice immunized with different combinations of HBV adenoviral vectors and HBV MVA; HBV core and polymerase peptide pools used to stimulate splenocytes isolated from the various vaccinated animal groups are indicated in black (core) and grey (pol); Poll and pol2 responses were summed; the X-axis shows the adenovirus vector dose and the presence or absence of the MVA boost. The percentages of CD8(+) T cells positive for IFN g are shown on the y-axis;
  • FIG. 5 shows a graph of ICS responses of Fl mice immunized with different combinations of HBV adenoviral vectors and HBV MVA vectors; HBV core and polymerase peptide pools used to stimulate splenocytes isolated from the various vaccinated animal groups are indicated in black (core) and grey (pol); Poll and pol2 responses were summed; the X-axis shows the adenoviral vector dose and the presence or absence of the MVA boost; the percentages of CD4(+) T cells positive for IFN g are shown on the y-axis;
  • FIG. 6 shows a graph of ELISPOT responses of NHPs immunized with different combinations of HBV adenoviral vectors and HBV MVA vectors; HBV core or polymerase peptide pools used to stimulate PBMCs isolated from the various vaccinated animal groups are indicated in squares (core), circles (poll) and triangles (pol2); the X- axis shows the different experimental groups and timepoints.
  • the number of responsive T- cells are indicated on the y-axis expressed as spot forming cells (SFC) per 10 6 splenocytes; background (medium + DMSO stimulation) subtracted data is shown; and
  • SFC spot forming cells
  • FIGS. 7A, 7B and 7C show graphs of ICS responses of NHPs immunized with different combinations of HBV adenoviral vectors and HBV MVA vectors; HBV core and polymerase peptide pools used to stimulate PBMCs isolated from the various vaccinated animal groups are indicated in squares (core), circles (poll) and triangles (pol2); the X- axis shows the different experimental groups and time points; the percentages of CD4(+) and CD8(+) T cells positive for IFN g are shown on the y-axis; background (medium + DMSO stimulation) subtracted data is shown.
  • any numerical values such as a concentration or a concentration range described herein, are to be understood as being modified in all instances by the term“about.”
  • a numerical value typically includes ⁇ 10% of the recited value.
  • a concentration of 1 mg/mL includes 0.9 mg/mL to 1.1 mg/mL.
  • a concentration range of 1% to 10% (w/v) includes 0.9% (w/v) to 11% (w/v).
  • the use of a numerical range expressly includes all possible subranges, all individual numerical values within that range, including integers within such ranges and fractions of the values unless the context clearly indicates otherwise.
  • the conjunctive term“and/or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by“and/or,” a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and therefore satisfy the requirement of the term“and/or” as used herein.
  • “subject” means any animal, preferably a mammal, most preferably a human, to whom will be or has been treated by a method according to an embodiment of the application.
  • the term“mammal” as used herein, encompasses any mammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, non-human primates (NHPs), such as monkeys or apes, humans, etc., more preferably a human.
  • adjuvant and “immune stimulant” are used interchangeably herein, and are defined as one or more substances that cause stimulation of the immune system.
  • an adjuvant is used to enhance an immune response to the adenovirus and/or MVA vectors of the application.
  • nucleic acids or polypeptide sequences e.g., HBV antigenic polypeptides and polynucleotides that encode them
  • sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection.
  • sequence comparison typically one sequence acts as a reference sequence, to which test sequences are compared.
  • test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated.
  • sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
  • Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat’l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics
  • BLAST and BLAST 2.0 algorithms are described in Altschul et al. (1990) J. Mol. Biol. 215: 403-410 and Altschul et al. (1997) Nucleic Acids Res. 25: 3389-3402, respectively.
  • Software for performing BLAST analyses is publicly available through the National Center for Biotechnology
  • This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al, supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased.
  • HSPs high scoring sequence pairs
  • Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always ⁇ 0).
  • M forward score for a pair of matching residues; always > 0
  • N penalty score for mismatching residues; always ⁇ 0.
  • a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
  • the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
  • the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix ( ee Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89: 10915 (1989)).
  • the BLAST algorithm In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat’l. Acad. Sci. USA 90:5873-5787 (1993)).
  • One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
  • a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
  • a further indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid, as described below.
  • a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions.
  • Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions, as described below.
  • the term“enhanced” when used with respect to an immune response refers to an increase in the immune response in a subject administered with a prime-boost combination of MV A and adenovirus vectors according to the application, relative to the corresponding immune response observed from the subject administered with an MVA vector or an adenovirus of the application alone.
  • CD4+ or CD8+T cell response refers to a T cell immune response that is characterized by observing a high proportion of immunogen- specific CD4+ T cells or CD8+ T cells within the population of total responding T cells following vaccination.
  • the total immunogen-specific T-cell response can be determined by an IFN-gamma ELISPOT assay.
  • the immunogen-specific CD4+ or CD8+ T cell immune response can be determined by an ICS assay.
  • the term“enhanced antibody response” refers to an increased antibody response in a subject administered with a prime-boost combination of MVA and adenovirus vectors according to the application, relative to the corresponding immune response observed from the subject administered with an MVA vector or an adenovirus of the application alone.
  • adjuvant is defined as one or more substances that cause stimulation of the immune system.
  • an adjuvant is used to enhance an immune response to the plasmid, adenovirus, and/or MVA vectors of the application.
  • an antigenic gene product or fragment thereof can include a bacterial, viral, parasitic, or fungal protein, or a fragment thereof.
  • an antigenic protein or antigenic gene product is capable of raising in a host a protective immune response, e.g., inducing an immune response against a disease or infection (e.g., a bacterial, viral, parasitic, or fungal disease or infection), and/or producing an immunity in (i.e., vaccinating) a subject against a disease or infection, that protects the subject against the disease or infection.
  • HBV vectors of the application may contain particular components, including, but not limited to, certain promoter sequences, enhancer or regulatory sequences, signal peptides, coding sequence of an HBV antigen, polyadenylation signal sequences, etc. arranged in a particular order
  • certain promoter sequences, enhancer or regulatory sequences, signal peptides, coding sequence of an HBV antigen, polyadenylation signal sequences, etc. arranged in a particular order
  • the concepts disclosed herein may equally apply to other components arranged in other orders that can be used in HBV vectors of the application.
  • the application contemplates use of any of the applicable components in any combination having any sequence that can be used in HBV vectors of the application, whether or not a particular combination is expressly described.
  • HBV Hepatitis B Virus
  • hepatitis B virus or“HBV” refers to a virus of the
  • HBV is a small (e.g., 3.2 kb) hepatotropic DNA virus that encodes four open reading frames and seven proteins. See FIG. 1A.
  • the seven proteins encoded by HBV include small (S), medium (M), and large (L) surface antigen (HBsAg) or envelope (Env) proteins, pre-Core protein, core protein, viral polymerase (Pol), and HBx protein.
  • HBV expresses three surface antigens, or envelope proteins, L, M, and S, with S being the smallest and L being the largest.
  • the extra domains in the M and L proteins are named Pre-S2 and Pre-Sl, respectively.
  • Core protein is the subunit of the viral nucleocapsid.
  • Pol is needed for synthesis of viral DNA (reverse transcriptase, RNaseH, and primer), which takes place in nucleocapsids localized to the cytoplasm of infected hepatocytes.
  • PreCore is the core protein with an N-terminal signal peptide and is proteolytically processed at its N and C termini before secretion from infected cells, as the so-called hepatitis B e-antigen (HBeAg).
  • HBx protein is required for efficient transcription of covalently closed circular DNA (cccDNA).
  • HBx is not a viral structural protein. All viral proteins of HBV have their own mRNA except for core and
  • the HBV virion contains a viral envelope, nucleocapsid, and single copy of the partially double-stranded DNA genome.
  • the nucleocapsid comprises 120 dimers of core protein and is covered by a capsid membrane embedded with the S, M, and L viral envelope or surface antigen proteins.
  • rcDNA capsid-containing relaxed circular DNA
  • phosphorylation of the Core protein induces structural changes, exposing a nuclear localization signal enabling interaction of the capsid with so-called importins.
  • rccDNA covalently closed circular DNA genome from which overlapping transcripts encode for HBeAg, HBsAg, Core protein, viral polymerase and HBx protein.
  • Core protein, viral polymerase, and pre-genomic RNA (pgRNA) associate in the cytoplasm and self-assemble into immature pgRNA-containing capsid particles, which further convert into mature rcDNA-capsids and function as a common
  • HBV is divided into four serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on the envelope proteins, and into eight genotypes (A, B, C, D, E, F, G, and H) based on the sequence of the viral genome.
  • the HBV genotypes are distributed over different geographic regions. For example, the most prevalent genotypes in Asia are genotypes B and C. Genotype D is dominant in Africa, the Middle East, and India, whereas genotype A is widespread in Northern Europe, sub-Saharan Africa, and West Africa.
  • the terms“HBV antigen,”“antigenic polypeptide of HBV,” “HBV antigenic polypeptide,”“HBV antigenic protein,”“HBV immunogenic polypeptide,” and“HBV immunogen” all refer to a polypeptide capable of inducing an immune response, e.g., a humoral and/or cellular mediated response, against an HBV in a subject.
  • the HBV antigen can be a polypeptide of HBV, a fragment or epitope thereof, or a combination of multiple HBV polypeptides, portions or derivatives thereof.
  • an HBV antigen is capable of raising in a host a protective immune response, e.g., inducing an immune response against a viral disease or infection, and/or producing an immunity (i.e., vaccinates) a subject against a viral disease or infection, that protects the subject against the viral disease or infection.
  • an HBV antigen can comprise a polypeptide or immunogenic fragment(s) thereof from any HBV protein, such as HBeAg, pre-core protein, HBsAg (S, M, or L proteins), core protein, viral polymerase, or HBx protein derived from any HBV genotype, e.g., genotype A, B, C, D, E, F, G, and/or H, or combination thereof.
  • each of the terms“HBV core antigen,”“HBeAg” and“core antigen” refers to an HBV antigen capable of inducing an immune response, e.g., a humoral and/or cellular mediated response, against an HBV core protein in a subject.
  • Each of the terms“core,”“core polypeptide,” and“core protein” refers to the HBV viral core protein.
  • Full-length core antigen is typically 183 amino acids in length and includes an assembly domain (amino acids 1 to 149) and a nucleic acid binding domain (amino acids 150 to 183). The 34-residue nucleic acid binding domain is required for pre- genomic RNA encapsidation.
  • HBV core protein is dimeric in solution, with the dimers self-assembling into icosahedral capsids. Each dimer of core protein has four a-helix bundles flanked by an a-helix domain on either side. Truncated HBV core proteins lacking the nucleic acid binding domain are also capable of forming capsids.
  • an HBV antigen is a truncated HBV core antigen.
  • a“truncated HBV core antigen,” refers to an HBV antigen that does not contain the entire length of an HBV core protein but is capable of inducing an immune response against the HBV core protein in a subject.
  • an HBV core antigen can be modified to delete one or more amino acids of the highly positively charged (arginine rich) C-terminal nucleic acid binding domain of the core antigen, which typically contains seventeen arginine (R) residues.
  • an HBV core antigen is a truncated HBV core protein.
  • a truncated HBV core antigen of the application is preferably a C-terminally truncated HBV core protein which does not comprise the HBV core nuclear import signal and/or a truncated HBV core protein from which the C-terminal HBV core nuclear import signal has been deleted.
  • a truncated HBV core antigen comprises a deletion in the C-terminal nucleic acid binding domain, such as a deletion of 1 to 34 amino acid residues of the C-terminal nucleic acid binding domain, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
  • a truncated HBV core antigen comprises a deletion in the C-terminal nucleic acid binding domain, preferably all 34 amino acid residues.
  • an HBV core antigen can be a consensus sequence derived from multiple HBV genotypes (e.g., genotypes A, B, C, D,
  • “consensus sequence” means an artificial sequence of amino acids based on an alignment of amino acid sequences of homologous proteins, e.g., as determined by an alignment (e.g., using Clustal Omega) of amino acid sequences of homologous proteins. It can be the calculated order of most frequent amino acid residues, found at each position in a sequence alignment, based upon sequences of HBV antigens (e.g., core, pol, etc.) from at least 100 natural HBV isolates. A consensus sequence can be non-naturally occurring and different from the native viral sequences.
  • Consensus sequences can be designed by aligning multiple HBV antigen sequences from different sources using a multiple sequence alignment tool, and at variable alignment positions, selecting the most frequent amino acid.
  • a consensus sequence of an HBV antigen is derived from HBV genotypes B, C, and D.
  • the term“consensus antigen” is used to refer to an antigen having a consensus sequence.
  • a truncated HBV core antigen lacks the nucleic acid binding function, and is capable of inducing an immune response in a mammal against at least two HBV genotypes.
  • the truncated HBV core antigen is capable of inducing a T cell response in a mammal against at least HBV genotypes B, C and D.
  • the truncated HBV core antigen is capable of inducing a CD8 T cell response in a human subject against at least HBV genotypes A, B, C and D.
  • an HBV core antigen is a consensus antigen, preferably a consensus antigen derived from HBV genotypes B, C, and D, more preferably a truncated consensus antigen derived from HBV genotypes B, C, and D.
  • An exemplary truncated HBV core consensus antigen consists of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100% identical to SEQ ID NO: 2.
  • SEQ ID NO: 2 is a core consensus antigen derived from HBV genotypes B, C, and D.
  • SEQ ID NO: 2 contains a 34-amino acid C- terminal deletion of the highly positively charged (arginine rich) nucleic acid binding domain of the native core antigen.
  • an HBV core antigen is a truncated HBV antigen consisting of the amino acid sequence of SEQ ID NO: 2.
  • the term“HBV polymerase antigen,”“HBV Pol antigen” or “HBV pol antigen” refers to an HBV antigen capable of inducing an immune response, e.g., a humoral and/or cellular mediated response, against an HBV polymerase in a subject.
  • Each of the terms“polymerase,”“polymerase polypeptide,”“Pol” and“pol” refers to the HBV viral DNA polymerase.
  • the HBV viral DNA polymerase has four domains, including, from the N terminus to the C terminus, a terminal protein (TP) domain, which acts as a primer for minus-strand DNA synthesis; a spacer that is nonessential for the polymerase functions; a reverse transcriptase (RT) domain for transcription; and a RNase H domain.
  • TP terminal protein
  • RT reverse transcriptase
  • an HBV antigen comprises an HBV Pol antigen, or any immunogenic fragment or combination thereof.
  • the HBV Pol antigen can contain further modifications to improve immunogenicity of the antigen, such as by introducing mutations into the active sites of the polymerase and/or RNase domains to decrease or substantially eliminate certain enzymatic activities.
  • an HBV Pol antigen of the application does not have reverse transcriptase activity and RNase H activity, and can be capable of inducing an immune response in a mammal against at least two HBV genotypes.
  • the HBV Pol antigen is capable of inducing a T cell response in a mammal against at least HBV genotypes B, C and D. More preferably, the HBV Pol antigen is capable of inducing a CD8 T cell response in a human subject against at least HBV genotypes A, B, C and D.
  • an HBV Pol antigen is an inactivated Pol antigen.
  • an inactivated HBV Pol antigen comprises one or more amino acid mutations in the active site of the polymerase domain.
  • an inactivated HBV Pol antigen comprises one or more amino acid mutations in the active site of the RNaseH domain.
  • an inactivated HBV pol antigen comprises one or more amino acid mutations in the active site of both the polymerase domain and the RNaseH domain.
  • the“YXDD” motif in the polymerase domain of the HBV pol antigen required for nucleotide/metal ion binding can be mutated, e.g., by replacing one or more of the aspartate residues (D) with asparagine residues (N), eliminating or reducing metal coordination function, thereby decreasing or substantially eliminating reverse transcriptase function.
  • the“DEDD” motif in the RNaseH domain of the HBV pol antigen required for Mg2+ coordination can be mutated, e.g., by replacing one or more aspartate residues (D) with asparagine residues (N) and/or replacing the glutamate residue (E) with glutamine (Q), thereby decreasing or substantially eliminating RNaseH function.
  • an HBV pol antigen is modified by (1) mutating the aspartate residues (D) to asparagine residues (N) in the“YXDD” motif of the polymerase domain; and (2) mutating the first aspartate residue (D) to an asparagine residue (N) and the first glutamate residue (E) to a glutamine residue (N) in the“DEDD” motif of the RNaseH domain, thereby decreasing or substantially eliminating both the reverse transcriptase and RNaseH functions of the pol antigen.
  • an HBV pol antigen is a consensus antigen, preferably a consensus antigen derived from HBV genotypes B, C, and D, more preferably an inactivated consensus antigen derived from HBV genotypes B, C, and D.
  • An exemplary HBV pol consensus antigen according to the application comprises an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%,
  • SEQ ID NO: 4 is a pol consensus antigen derived from HBV genotypes B, C, and D comprising four mutations located in the active sites of the polymerase and RNaseH domains.
  • the four mutations include mutation of the aspartic acid residues (D) to asparagine residues (N) in the “YXDD” motif of the polymerase domain; and mutation of the first aspartate residue (D) to an asparagine residue (N) and mutation of the glutamate residue (E) to a glutamine residue (Q) in the“DEDD” motif of the RNaseH domain.
  • an HBV pol antigen comprises the amino acid sequence of SEQ ID NO: 4.
  • an HBV pol antigen consists of the amino acid sequence of SEQ ID NO: 4.
  • fusion protein or“fusion” refers to a single polypeptide chain having at least two polypeptide domains that are not normally present in a single, natural polypeptide.
  • an HBV antigen comprises a fusion protein comprising a truncated HBV core antigen operably linked to a HBV pol antigen, or a HBV pol antigen operably linked to a truncated HBV core antigen, preferably via a linker.
  • linker refers to a compound or moiety that acts as a molecular bridge to operably link two different molecules, wherein one portion of the linker is operably linked to a first molecule, and wherein another portion of the linker is operably linked to a second molecule.
  • a linker serves primarily as a spacer between the first and second polypeptides.
  • the linker is made up of amino acids linked together by peptide bonds, preferably from 1 to 20 amino acids linked by peptide bonds, wherein the amino acids are selected from the 20 naturally occurring amino acids.
  • the 1 to 20 amino acids are selected from glycine, alanine, proline, asparagine, glutamine, and lysine.
  • a linker is made up of a majority of amino acids that are sterically unhindered, such as glycine and alanine.
  • Exemplary linkers are polyglycines, particularly (Gly)5, (Gly)8; poly(Gly-Ala), and polyalanines.
  • One exemplary suitable linker as shown in the Examples below is
  • n is an integer of 2 to 5.
  • a fusion protein of the application is capable of inducing an immune response in a mammal against HBV core and HBV Pol of at least two HBV genotypes.
  • the fusion protein is capable of inducing a T cell response in a mammal against at least HBV genotypes B, C and D.
  • the fusion protein is capable of inducing a CD8 T cell response in a human subject against at least HBV genotypes A, B, C and D.
  • a fusion protein comprises a truncated HBV core antigen having an amino acid sequence at least 90%, such as at least 90%,
  • a fusion protein comprises a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2, a linker comprising (AlaGly) n , wherein n is an integer of 2 to 5, and a HBV Pol antigen having the amino acid sequence of SEQ ID NO: 4. More preferably, a fusion protein according to an embodiment of the application comprises the amino acid sequence of SEQ ID NO: 12.
  • a fusion protein further comprises a signal sequence.
  • the signal sequence has the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 11. More preferably, the fusion protein comprises the amino acid sequence of SEQ ID NO: 13.
  • the application provides a non-naturally occurring nucleic acid molecule encoding an HBV antigen according to an embodiment of the application, and a vector comprising the non-naturally occurring nucleic acid.
  • a non-naturally occurring nucleic acid molecule can comprise any polynucleotide sequence encoding an HBV antigen of the application, which can be made using methods known in the art in view of the present disclosure.
  • a polynucleotide encodes at least one of an HBV core antigen and an HBV polymerase antigen of the application.
  • a polynucleotide can be in the form of RNA or in the form of DNA obtained by recombinant techniques (e.g., cloning) or produced synthetically (e.g., chemical synthesis).
  • the DNA can be single-stranded or double-stranded, or can contain portions of both double-stranded and single-stranded sequence.
  • the DNA can, for example, comprise genomic DNA, cDNA, or combinations thereof.
  • the polynucleotide can also be a DNA/RNA hybrid.
  • the polynucleotides and vectors of the application can be used for recombinant protein production, expression of the protein in a host cell, or the production of viral particles.
  • a polynucleotide is DNA.
  • a non-naturally occurring nucleic acid molecule comprises a polynucleotide encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 2, preferably at least 98%, 99% or 100% identical to SEQ ID NO: 2.
  • a non-naturally occurring nucleic acid molecule encodes a truncated HBV core antigen comprising the amino acid sequence of SEQ ID NO: 2.
  • polynucleotide sequences of the application encoding a truncated HBV core antigen comprising the amino acid sequence of SEQ ID NO: 2 include, but are not limited to, a polynucleotide sequence at least 90% identical to SEQ ID NO: 1, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%,
  • the non-naturally occurring nucleic acid molecule encoding a truncated HBV core antigen comprises the
  • a non-naturally occurring nucleic acid molecule encodes a HBV polymerase antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, such as at least 90%, 91%, 92%, 93%, 94%,
  • a non-naturally occurring nucleic acid molecule encodes a HBV polymerase antigen comprising the amino acid sequence of SEQ ID NO: 4.
  • Examples of polynucleotide sequences of the application encoding a HBV Pol antigen comprising the amino acid sequence of SEQ ID NO: 4 include, but are not limited to, a polynucleotide sequence at least 90% identical to SEQ ID NO: 3, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 3, preferably at least 98%, 99% or 100% identical to SEQ ID NO: 3.
  • the non-naturally occurring nucleic acid molecule encoding a HBV pol antigen comprises the polynucleotide sequence of SEQ ID NOs: 3, 19, or 20.
  • a non-naturally occurring nucleic acid molecule encodes a fusion protein comprising a truncated HBV core antigen operably linked to a HBV Pol antigen, or a HBV Pol antigen operably linked to a truncated HBV core antigen.
  • a non-naturally occurring nucleic acid molecule of the application encodes a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 2, preferably 100% identical to SEQ ID NO: 2; a linker; and a HBV polymerase antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%,
  • a non-naturally occurring nucleic acid molecule encodes a fusion protein comprising a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2, a linker comprising (AlaGly)n, wherein n is an integer of 2 to 5; and a HBV Pol antigen comprising the amino acid sequence of SEQ ID NO: 4.
  • a non- naturally occurring nucleic acid molecule encodes a fusion protein comprising the amino acid sequence of SEQ ID NO: 12.
  • polynucleotide sequences of the application encoding a fusion protein include, but are not limited to, a polynucleotide sequence at least 90% identical to SEQ ID NO: 1, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 1, preferably at least 98%, 99% or 100% identical to SEQ ID NO: 1, operably linked to a linker coding sequence at least 90% identical to SEQ ID NO: 14, such as at least 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.
  • a non-naturally occurring nucleic acid molecule encoding a fusion protein comprises SEQ ID NO: 1, operably linked to SEQ ID NO: 14, which is further operably linked to SEQ ID NO: 3.
  • the application relates to a vector comprising an isolated polynucleotide encoding an HBV antigen.
  • a“vector” is a nucleic acid molecule used to carry genetic material into another cell, where it can be replicated and/or expressed. Any vector known to those skilled in the art in view of the present disclosure can be used. Examples of vectors include, but are not limited to, plasmids, viral vectors (bacteriophage, animal viruses, and plant viruses), cosmids, and artificial chromosomes (e.g., YACs).
  • a vector is a DNA plasmid.
  • a vector can be a DNA vector or an RNA vector.
  • One of skill in the art can construct a vector of the application through standard recombinant techniques in view of the present disclosure.
  • a vector can be an expression vector.
  • expression vector refers to any type of genetic construct comprising a nucleic acid coding for an RNA capable of being transcribed.
  • Expression vectors include, but are not limited to, vectors for recombinant protein expression, such as a DNA plasmid or a viral vector, and vectors for delivery of nucleic acid into a subject for expression in a tissue of the subject, such as a DNA plasmid or a viral vector. It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc.
  • Vectors according to embodiments of the application can contain a variety of regulatory sequences.
  • regulatory sequence refers to any sequence that allows, contributes or modulates the functional regulation of the nucleic acid molecule, including replication, duplication, transcription, splicing, translation, stability and/or transport of the nucleic acid or one of its derivative (i.e. mRNA) into the host cell or organism.
  • this term encompasses promoters, enhancers and other expression control elements (e.g., polyadenylation signals and elements that affect mRNA stability).
  • a vector is a non-viral vector.
  • non-viral vectors include, but are not limited to, DNA plasmids, bacterial artificial chromosomes, yeast artificial chromosomes, bacteriophages, etc.
  • a non-viral vector is a DNA plasmid.
  • A“DNA plasmid,” which is used interchangeably with“DNA plasmid vector,”“plasmid DNA” or“plasmid DNA vector,” refers to a double-stranded and generally circular DNA sequence that is capable of autonomous replication in a suitable host cell.
  • DNA plasmids used for expression of an encoded polynucleotide typically comprise an origin of replication, a multiple cloning site, and a selectable marker, which for example, can be an antibiotic resistance gene.
  • DNA plasmids suitable for use in the application include, but are not limited to, commercially available expression vectors for use in well-known expression systems (including both prokaryotic and eukaryotic systems), such as pSE420 (Invitrogen, San Diego, Calif.), which can be used for production and/or expression of protein in
  • Escherichia coli Escherichia coli
  • pYES2 Invitrogen, Thermo Fisher Scientific
  • MAXBAC® complete baculovirus expression system Thermo Fisher Scientific
  • pcDNATM or pcDNA3TM Lifetime DNA sequences
  • Thermo Fisher Scientific which can be used for high level constitutive protein expression in mammalian cells
  • pVAX or pVAX-l Life Technologies, Thermo Fisher Scientific
  • the backbone of any commercially available DNA plasmid can be modified to optimize protein expression in the host cell, such as to reverse the orientation of certain elements (e.g., origin of replication and/or antibiotic resistance cassette), replace a promoter endogenous to the plasmid (e.g., the promoter in the antibiotic resistance cassette), and/or replace the polynucleotide sequence encoding transcribed proteins (e.g., the coding sequence of the antibiotic resistance gene), by using routine techniques and readily available starting materials. (See e.g., Sambrook et al, Molecular Cloning a Laboratory Manual, Second Ed. Cold Spring Harbor Press (1989)).
  • a DNA plasmid is an expression vector suitable for protein expression in mammalian host cells.
  • Expression vectors suitable for protein expression in mammalian host cells include, but are not limited to, pcDNATM, pcDNA3TM, pVAX, pVAX-l, AD VAX, NTC8454, etc.
  • the expression vector is based on pVAX-l, which can be further modified to optimize protein expression in mammalian cells.
  • pVAX-l is a commonly used plasmid in DNA vaccines, and contains a strong human immediate early cytomegalovirus (CMV-IE) promoter followed by the bovine growth hormone (bGH)-derived polyadenylation sequence (pA).
  • CMV-IE human immediate early cytomegalovirus
  • bGH bovine growth hormone-derived polyadenylation sequence
  • pVAX-l further contains a pUC origin of replication and kanamycin resistance gene driven by a small prokaryotic promoter that allows for bacterial plasmid propagation.
  • a vector is a viral vector.
  • viral vectors are genetically engineered viruses carrying modified viral DNA or RNA that has been rendered non-infectious, but still contains viral promoters and transgenes, thus allowing for translation of the transgene through a viral promoter. Because viral vectors are frequently lacking infectious sequences, they require helper viruses or packaging lines for large-scale transfection.
  • viral vectors suitable for use with the application include, but are not limited to adenoviral vectors, Modified Vaccinia Ankara (MV A) vectors, adeno-associated virus vectors, pox virus vectors, enteric virus vectors, Venezuelan Equine Encephalitis virus vectors, Semliki Forest Virus vectors, Tobacco Mosaic Virus vectors, lentiviral vectors, etc.
  • MV A Modified Vaccinia Ankara
  • adeno-associated virus vectors adeno-associated virus vectors
  • pox virus vectors pox virus vectors
  • enteric virus vectors Venezuelan Equine Encephalitis virus vectors
  • Semliki Forest Virus vectors Semliki Forest Virus vectors
  • Tobacco Mosaic Virus vectors Tobacco Mosaic Virus vectors
  • lentiviral vectors etc.
  • a vector e.g., a DNA plasmid or a viral vector
  • Regulatory elements include, but are not limited to, a promoter, an enhancer, a polyadenylation signal, translation stop codon, a ribosome binding element, a transcription terminator, selection markers, origin of replication, etc.
  • a vector can comprise one or more expression cassettes.
  • An“expression cassette” is part of a vector that directs the cellular machinery to make RNA and protein.
  • An expression cassette typically comprises three components: a promoter sequence, an open reading frame, and a 3’-untranslated region (ETTR) optionally comprising a polyadenylation signal.
  • An open reading frame is a reading frame that contains a coding sequence of a protein of interest (e.g., HBV antigen) from a start codon to a stop codon.
  • Regulatory elements of the expression cassette can be operably linked to a polynucleotide sequence encoding an HBV antigen of interest.
  • the term“operably linked” is to be taken in its broadest reasonable context, and refers to a linkage of polynucleotide elements in a functional relationship.
  • a polynucleotide is“operably linked” when it is placed into a functional relationship with another polynucleotide.
  • a promoter is operably linked to a coding sequence if it affects the transcription of the coding sequence.
  • a vector comprises a promoter sequence, preferably within an expression cassette, to control expression of an HBV antigen of interest.
  • promoter is used in its conventional sense, and refers to a nucleotide sequence that initiates the transcription of an operably linked nucleotide sequence.
  • a promoter is located on the same strand near the nucleotide sequence it transcribes. Promoters can be a constitutive, inducible, or repressible. Promoters can be naturally occurring or synthetic.
  • a promoter can be derived from sources including, viral, bacterial, fungal, plants, insects, and animals.
  • a promoter can be a homologous promoter (i.e., derived from the same genetic source as the vector) or a heterologous promoter (i.e., derived from a different vector or genetic source).
  • the promoter can be endogenous to the plasmid (homologous) or derived from other sources (heterologous).
  • the promoter is located upstream of the polynucleotide encoding an HBV antigen within an expression cassette.
  • promoters suitable for use in the application include, but are not limited to, a promoter from simian virus 40 (SV40), a mouse mammary tumor virus (MMTV) promoter, a human immunodeficiency virus (HIV) promoter such as the bovine immunodeficiency virus (BIV) long terminal repeat (LTR) promoter, a Moloney virus promoter, an avian leukosis virus (ALV) promoter, a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter (CMV-IE), Epstein Barr virus (EBV) promoter, or a Rous sarcoma virus (RSV) promoter.
  • Additional promoters suitable for use in the application include, but are not limited to, an RSV promoter, the retrovirus LTR, the adenovirus major late promoter, and various poxvirus promoters including, but not limited to the following vaccinia virus or MVA-derived and FPV-derived promoters: the 3 OK promoter, the 13 promoter, the PrS promoter, the PrHyb, the PrS5E promoter, the Pr7.5K, the Prl3.5 long promoter, the 40K promoter, the MVA-40K promoter, the FPV 40K promoter, 30k promoter, the PrSynllm promoter, the PrLEl promoter, and the PR1238 promoter. Additional promoters are further described in WO 2010/060632, WO 2010/102822, WO 2013/189611 and WO 2014/063832, and WO2017/021776, which are incorporated fully by reference herein.
  • a promoter can also be a promoter from a human gene such as human actin, human myosin, human hemoglobin, human muscle creatine, or human metalothionein.
  • a promoter can also be a tissue specific promoter, such as a muscle or skin specific promoter, natural or synthetic.
  • a promoter is a strong eukaryotic promoter, preferably a cytomegalovirus immediate early (CMV-IE) promoter.
  • CMV-IE cytomegalovirus immediate early
  • a promoter is a poxviral promoter, preferably a promoter selected from PrMVA 13.5 long and/or PrHyb.
  • Nucleotide sequences for an exemplary Prl3.5 long promoter and a PrHyb promoter are shown as SEQ ID NO:25 and 26, respectively.
  • a vector comprises additional polynucleotide sequences that stabilize the expressed transcript, enhance nuclear export of the RNA transcript, and/or improve transcriptional-translational coupling.
  • sequences include polyadenylation signals and enhancer sequences.
  • a polyadenylation signal is typically located downstream of the coding sequence for a protein of interest (e.g., an HBV antigen) within an expression cassette of the vector.
  • Enhancer sequences are regulatory DNA sequences that, when bound by transcription factors, enhance the transcription of an associated gene.
  • An enhancer sequence is preferably located upstream of the polynucleotide sequence encoding an HBV antigen, but downstream of a promoter sequence within an expression cassette of the vector.
  • the polyadenylation signal can be a SV40 polyadenylation signal (e.g., SEQ ID NO: 16), LTR polyadenylation signal, bovine growth hormone (bGH) polyadenylation signal, human growth hormone (hGH) polyadenylation signal, or human b-globin polyadenylation signal.
  • a polyadenylation signal is a bovine growth hormone (bGH) polyadenylation signal.
  • bGH bovine growth hormone
  • polyadenylation signal is shown in SEQ ID NO: 9.
  • an enhancer sequence can be human actin, human myosin, human hemoglobin, human muscle creatine, or a viral enhancer, such as one from CMV, HA, RSV, or EBV.
  • WPRE Woodchuck HBV Post-transcriptional regulatory element
  • HTLV-l human T-cell leukemia virus type 1
  • LTR long terminal repeat
  • splicing enhancer a synthetic rabbit b-globin intron, or any combination thereof.
  • an enhancer sequence is a composite sequence of three consecutive elements of the untranslated R-U5 domain of HTLV-l LTR, rabbit b-globin intron, and a splicing enhancer, which is referred to herein as“a triple enhancer sequence.”
  • a nucleotide sequence of an exemplary triple enhancer sequence is shown in SEQ ID NO: 8.
  • Another exemplary enhancer sequence is an ApoAI gene fragment shown in SEQ ID NO: 15.
  • a vector comprises a polynucleotide sequence encoding a signal peptide sequence.
  • the polynucleotide sequence encoding the signal peptide sequence is located upstream of the polynucleotide sequence encoding an HBV antigen.
  • Signal peptides typically direct localization of a protein, facilitate secretion of the protein from the cell in which it is produced, and/or improve antigen expression and cross-presentation to antigen-presenting cells.
  • a signal peptide can be present at the N- terminus of an HBV antigen when expressed from the vector, but is cleaved off by signal peptidase, e.g., upon secretion from a cell.
  • a signal peptide can be a cystatin S signal peptide; an immunoglobulin (Ig) secretion signal, such as the Ig heavy chain gamma signal peptide SPIgG or the Ig heavy chain epsilon signal peptide SPIgE.
  • Ig immunoglobulin
  • a signal peptide sequence is a cystatin S signal peptide.
  • Exemplary nucleic acid and amino acid sequences of a cystatin S signal peptide are shown in SEQ ID NOs: 5 and 6, respectively.
  • Exemplary nucleic acid and amino acid sequences of an immunoglobulin secretion signal are shown in SEQ ID NOs: 10 and 27 and SEQ ID NO: 11, respectively.
  • a vector such as a DNA plasmid
  • Bacterial origins of replication and antibiotic resistance cassettes can be located in a vector in the same orientation as the expression cassette encoding an HBV antigen, or in the opposite (reverse) orientation.
  • An origin of replication is a sequence at which replication is initiated, enabling a plasmid to reproduce and survive within cells.
  • ORIs suitable for use in the application include, but are not limited to ColEl, pMBl, pUC, pSClOl, R6K, and 15 A, preferably pUC.
  • An exemplary nucleotide sequence of a pUC ORI is shown in SEQ ID NO: 21.
  • Expression cassettes for selection and maintenance in bacterial cells typically include a promoter sequence operably linked to an antibiotic resistance gene.
  • the promoter sequence operably linked to an antibiotic resistance gene differs from the promoter sequence operably linked to a polynucleotide sequence encoding a protein of interest, e.g., HBV antigen.
  • the antibiotic resistance gene can be codon optimized, and the sequence composition of the antibiotic resistance gene is normally adjusted to bacterial, e.g., E. coli , codon usage.
  • Any antibiotic resistance gene known to those skilled in the art in view of the present disclosure can be used, including, but not limited to, kanamycin resistance gene (Kan r ), ampicillin resistance gene (Amp r ), and tetracycline resistance gene (Tet r ), as well as genes conferring resistance to chloramphenicol, bleomycin, spectinomycin, carbenicillin, etc.
  • Kan r kanamycin resistance gene
  • Amicillin resistance gene Amicillin resistance gene
  • Tet r tetracycline resistance gene
  • a vector is a viral vector, preferably an adenoviral vector, comprising an expression cassette including a polynucleotide encoding at least one of an HBV antigen selected from the group consisting of an HBV pol antigen comprising an amino acid sequence at least 98% identical to SEQ ID NO: 4, such as at least 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 4, and a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2; an upstream sequence operably linked to the polynucleotide encoding the HBV antigen comprising, from 5’ end to 3’ end, a promoter sequence, preferably a CMV-IE promoter sequence of SEQ ID NO: 7, an enhancer sequence, preferably a triple enhancer sequence of SEQ ID
  • polynucleotide sequence encoding a signal peptide sequence, preferably a cystatin S signal having the amino acid sequence of SEQ ID NO: 6 or an immunoglobulin secretion signal having the amino acid sequence of SEQ ID NO: 11 ; and a downstream sequence operably linked to the polynucleotide encoding the HBV antigen comprising a polyadenylation signal, preferably a SV40 polyadenylation signal of SEQ ID NO: 16 or a bGH polyadenylation signal of SEQ ID NO: 9.
  • a vector is a viral vector, preferably a MVA vector, comprising an expression cassette including a polynucleotide encoding at least one of an HBV antigen selected from the group consisting of an HBV pol antigen comprising an amino acid sequence at least 98% identical to SEQ ID NO: 4, such as at least 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 4, and a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2; an upstream sequence operably linked to the polynucleotide encoding the HBV antigen comprising, from 5’ end to 3’ end, a promoter sequence, preferably a PrMVAl3.5 long promoter sequence of SEQ ID NO: 25 or a PrHyb promoter sequence of SEQ ID NO: 26,
  • a vector such as a viral vector, encodes an HBV Pol antigen having the amino acid sequence of SEQ ID NO: 4.
  • the vector comprises a coding sequence for the HBV Pol antigen that is at least 90% identical to the polynucleotide sequence of SEQ ID NO: 3, such as 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%,
  • a vector such as a viral vector, encodes a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO:2.
  • the vector comprises a coding sequence for the truncated HBV core antigen that is at least 90% identical to the polynucleotide sequence of SEQ ID NO: l, such as 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%,
  • a vector such as a viral vector, encodes a fusion protein comprising an HBV Pol antigen having the amino acid sequence of SEQ ID NO: 4 and a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2.
  • the vector comprises a coding sequence for the fusion, which contains a coding sequence for the truncated HBV core antigen at least 90% identical to SEQ ID NO: l, such as 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: l, preferably 98%, 99% or 100% identical to SEQ ID NO: 1, operably linked to a coding sequence for the HBV Pol antigen at least 90% identical to SEQ ID NO: 3, such as 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%,
  • the coding sequence for the truncated HBV core antigen is operably linked to the coding sequence for the HBV Pol antigen via a coding sequence for a linker at least 90% identical to SEQ ID NO: 14, such as 90%, 91%, 92%, 93%, 94%, 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or 100% identical to SEQ ID NO: 14, preferably 98%, 99% or 100% identical to SEQ ID NO: 14.
  • the vector comprises a coding sequence for the fusion having SEQ ID NO: 1 operably linked to SEQ ID NO: 1 operably linked to SEQ ID NO:
  • polynucleotides and expression vectors encoding the HBV antigens of the application can be made by any method known in the art in view of the present disclosure.
  • a polynucleotide encoding an HBV antigen can be introduced or“cloned” into an expression vector using standard molecular biology techniques, e.g., polymerase chain reaction (PCR), etc., which are well known to those skilled in the art.
  • PCR polymerase chain reaction
  • the application provides a recombinant adenovirus comprising a heterologous nucleotide sequence encoding an antigenic HBV core antigen.
  • the application provides a adenovirus comprising a heterologous nucleotide sequence encoding an antigenic HBV pol antigen.
  • the application provides a recombinant adenovirus vector comprising a first heterologous nucleotide sequence encoding an antigenic HBV core antigen and a second heterologous nucleotide sequence encoding an antigenic HBV pol antigen.
  • the application provides a recombinant adenovirus comprising a heterologous nucleotide sequence encoding an antigenic HBV core-HBV pol fusion protein.
  • An adenovirus belongs to the family of the Adenoviridae and preferably is one that belongs to the genus Mastadenovirus. It can be a human adenovirus, but also an adenovirus that infects other species, including but not limited to a bovine adenovirus (e.g. bovine adenovirus 3, BAdV3), a canine adenovirus (e.g. CAdV2), a porcine adenovirus (e.g.
  • the adenovirus is a human adenovirus (HAdV, or AdHu; in the application a human adenovirus is meant if referred to as Ad without indication of species, e.g.
  • Ad5 means the same as HAdV5, which is human adenovirus serotype 5), or a simian adenovirus such as chimpanzee or gorilla adenovirus (ChAd, AdCh, or SAdV).
  • the recombinant adenovirus according to the application is based upon a human adenovirus.
  • the recombinant adenovirus is based upon a human adenovirus serotype 5, 11, 26, 34, 35, 48, 49 or 50.
  • an adenovirus is a human adenovirus of one of the serotypes 26 or 35.
  • rAd26 vectors Preparation of rAd26 vectors is described, for example, in WO 2007/104792 and in Abbink et al., (2007) Virol 81(9): 4654-63, both of which are incorporated by reference herein in their entirety.
  • Exemplary genome sequences of Ad26 are found in GenBank Accession EF 153474 and in W02007/104792 (see, e.g., SEQ ID NO: l).
  • Preparation of rAd35 vectors is described, for example, in ETS Patent No.
  • Simian adenoviruses generally also have a low seroprevalence and/or low pre existing neutralizing antibody titers in the human population, and a significant amount of work has been reported using chimpanzee adenovirus vectors (e.g. ETS6083716;
  • the recombinant adenovirus according to the application is based upon a simian adenovirus, e.g. a chimpanzee adenovirus.
  • the recombinant adenovirus is based upon simian adenovirus type 1, 3, 7, 8, 21, 22, 23, 24, 25, 26, 27.1, 28.1, 29, 30, 31.1, 32, 33, 34, 35.1, 36, 37.2, 39, 40.1, 41.1, 42.1, 43, 44, 45, 46, 48, 49, 50 or SA7P.
  • the adenoviral vectors comprise capsid proteins from two rare serotypes: Ad26 and Ad35.
  • the vector is an rAd26 or rAd35 virus.
  • the vectors that can be used in the application comprise an Ad26 or Ad35 capsid protein (e.g., a fiber, penton or hexon protein).
  • Ad26 or Ad35 capsid protein e.g., a fiber, penton or hexon protein.
  • chimeric capsid proteins that include at least a part of an Ad26 or Ad35 capsid protein can be used in the vectors of the application.
  • the vectors of the application may also comprise capsid proteins in which the fiber, penton, and hexon proteins are each derived from a different serotype, so long as at least one capsid protein is derived from Ad26 or Ad35.
  • the fiber, penton and hexon proteins are each derived from Ad26 or each from Ad35.
  • a chimeric adenovirus that combines desirable properties from different serotypes can be produced.
  • a chimeric adenovirus of the application could combine the absence of pre existing immunity of the Ad26 and Ad35 serotypes with characteristics such as temperature stability, assembly, anchoring, production yield, redirected or improved infection, stability of the DNA in the target cell, and the like.
  • the recombinant adenovirus vector useful in the application is derived mainly or entirely from Ad35 or from Ad26 (i.e., the vector is rAd35 or rAd26).
  • the adenovirus is replication deficient, e.g. because it contains a deletion in the El region of the genome.
  • Ad26 or Ad35 it is typical to exchange the E4-orf6 coding sequence of the adenovirus with the E4-orf6 of an adenovirus of human subgroup C, such as Ad5. This allows propagation of such adenoviruses in well-known
  • the adenovirus is a human adenovirus of serotype 35, with a deletion in the El region into which the nucleic acid encoding the antigen has been cloned, and with an E4 orf6 region of Ad5.
  • the adenovirus is a human adenovirus of serotype 26, with a deletion in the El region into which the nucleic acid encoding the antigen has been cloned, and with an E4 orf6 region of Ad5.
  • Ad35 adenovirus For the Ad35 adenovirus, it is typical to retain the 3’ end of the E1B 55K open reading frame in the adenovirus, for instance the 166 bp directly upstream of the pIX open reading frame or a fragment comprising this such as a 243 bp fragment directly upstream of the pIX start codon, marked at the 5’ end by a Bsu36I restriction site, since this increases the stability of the adenovirus because the promoter of the pIX gene is partly residing in this area (see, e.g. Havenga et al, 2006, supra; WO 2004/001032).
  • rAd26 vectors The preparation of recombinant adenoviral vectors is well known in the art. Preparation of rAd26 vectors is described, for example, in WO 2007/104792 and in Abbink et al., (2007) Virol 81(9): 4654-63. Exemplary genome sequences of Ad26 are found in GenBank Accession EF 153474 and in SEQ ID NO: l of WO 2007/104792. Preparation of rAd35 vectors is described, for example, in US Patent No. 7,270,811 and in Vogels et al, (2003) J Virol 77(15): 8263-71. An exemplary genome sequence of Ad35 is found in GenBank Accession AC 000019.
  • the vectors useful in the application include those described in WO2012/082918, the disclosure of which is incorporated herein by reference in its entirety.
  • a vector useful in the application is produced using a nucleic acid comprising the entire recombinant adenoviral genome (e.g., a plasmid, cosmid, or baculovirus vector).
  • the application also provides isolated nucleic acid molecules that encode the adenoviral vectors of the application.
  • the nucleic acid molecules of the application may be in the form of RNA or in the form of DNA obtained by cloning or produced synthetically.
  • the DNA may be double-stranded or single-stranded.
  • the adenovirus vectors useful in the application are typically replication defective.
  • the virus is rendered replication-defective by deletion or inactivation of regions critical to replication of the virus, such as the El region.
  • the regions can be substantially deleted or inactivated by, for example, inserting the gene of interest (usually linked to a promoter).
  • the vectors of the application may contain deletions in other regions, such as the E2, E3 or E4 regions or insertions of heterologous genes linked to a promoter.
  • E2- and/or E4-mutated adenoviruses generally E2- and/or E4-complementing cell lines are used to generate recombinant adenoviruses. Mutations in the E3 region of the adenovirus need not be complemented by the cell line, since E3 is not required for replication.
  • a packaging cell line is typically used to produce sufficient amount of adenovirus vectors of the application.
  • a packaging cell is a cell that comprises those genes that have been deleted or inactivated in a replication-defective vector, thus allowing the virus to replicate in the cell.
  • Suitable cell lines include, for example, PER.C6, 911, 293, and El A549.
  • HBV antigens e.g., HBV core and HBV polymerase antigens
  • the heterologous gene encoding the HBV antigen can be codon-optimized to ensure proper expression in the treated host (e.g., human). Codon-optimization is a technology widely applied in the art.
  • the heterologous gene is cloned into the El and/or the E3 region of the adenoviral genome.
  • the heterologous Hepatitis B virus gene may be under the control of (i.e., operably linked to) an adenovirus-derived promoter (e.g., the Major Late Promoter) or may be under the control of a heterologous promoter.
  • adenovirus-derived promoter e.g., the Major Late Promoter
  • suitable heterologous promoters include the CMV promoter and the RSV promoter.
  • the promoter is located upstream of the heterologous gene of interest within an expression cassette.
  • MVA vectors useful for the application utilize attenuated virus derived from Modified Vaccinia Ankara virus.
  • the MVA vectors express a wide variety of HBV antigens (e.g., HBV core and HBV polymerase antigens).
  • HBV antigens e.g., HBV core and HBV polymerase antigens.
  • the application provides a recombinant MVA vector comprising a heterologous nucleotide sequence encoding an antigenic HBV core antigen.
  • the application provides a recombinant MVA vector comprising a heterologous nucleotide sequence encoding an antigenic HBV pol antigen.
  • the application provides a recombinant MVA vector comprising a first heterologous nucleotide sequence encoding an antigenic HBV core antigen and a second heterologous nucleotide sequence encoding an antigenic HBV pol antigen.
  • the application provides a recombinant MVA vector comprising a heterologous nucleotide sequence encoding an antigenic HBV core-HBV pol fusion protein.
  • MV A man-made attenuated modified vaccinia virus Ankara
  • CVA Ankara strain of vaccinia virus
  • An MVA virus useful in the practice of the application can include, but is not limited to, MVA-572 (deposited as ECACC V94012707 on January 27, 1994); MVA-575 (deposited as ECACC V00120707 on December 7, 2000), MVA-I721 (referenced in Suter et al, Vaccine 2009), and ACAM3000 (deposited as ATCC® PTA-5095 on March 27, 2003).
  • the MVA used in accordance with the application includes MVA-BN and derivatives of MVA-BN.
  • MVA-BN has been described in International PCT publication WO 02/042480.“Derivatives” of MVA-BN refer to viruses exhibiting essentially the same replication characteristics as MVA-BN, as described herein, but exhibiting differences in one or more parts of their genomes.
  • MVA-BN is replication incompetent, meaning a failure to reproductively replicate in vivo and in vitro. More specifically in vitro, MVA- BN or derivatives thereof have been described as being capable of reproductive replication in chicken embryo fibroblasts (CEF), but not capable of reproductive replication in the human keratinocyte cell line HaCat (Boukamp et al (1988), J. Cell Biol. 106:761-771), the human bone osteosarcoma cell line 143B (ECACC Deposit No.
  • MVA-BN or derivatives thereof have a virus amplification ratio at least two fold less, more preferably three-fold less than MVA-575 in Hela cells and HaCaT cell lines. Tests and assay for these properties of MVA-BN and derivatives thereof are described in WO 02/42480 (U.S. Patent application No. 2003/0206926) and WO
  • the term“not capable of reproductive replication” or“no capability of reproductive replication” in human cell lines in vitro as described in the previous paragraphs is, for example, described in WO 02/42480, which also teaches how to obtain MVA having the desired properties as mentioned above.
  • the term applies to a virus that has a virus amplification ratio in vitro at 4 days after infection of less than 1 using the assays described in WO 02/42480 or in U.S. Patent No. 6,761,893.
  • the term“failure to reproductively replicate” refers to a virus that has a virus amplification ratio in human cell lines in vitro as described in the previous paragraphs at 4 days after infection of less than 1.
  • Assays described in WO 02/42480 or in U.S. Patent No. 6,761,893 are applicable for the determination of the virus amplification ratio.
  • the amplification or replication of a virus in human cell lines in vitro as described in the previous paragraphs is normally expressed as the ratio of virus produced from an infected cell (output) to the amount originally used to infect the cell in the first place (input) referred to as the“amplification ratio”.
  • An amplification ratio of“1” defines an amplification status where the amount of virus produced from the infected cells is the same as the amount initially used to infect the cells, meaning that the infected cells are permissive for virus infection and reproduction.
  • an amplification ratio of less than 1, i.e., a decrease in output compared to the input level indicates a lack of reproductive replication and therefore attenuation of the virus.
  • MVA-based vaccine has advantages as well as availability for large scale vaccine production. Preclinical tests have revealed that MVA- BN demonstrates superior attenuation and efficacy compared to other MVA strains (WO 02/42480). An additional property of MVA-BN strains is the ability to induce substantially the same level of immunity in vaccinia virus prime/vaccinia virus boost regimes when compared to DNA- prime/vaccinia virus boost regimes.
  • MVA-BN viruses are considered to be safe because of their distinct replication deficiency in mammalian cells and their well-established avirulence. Furthermore, in addition to its efficacy, the feasibility of industrial scale manufacturing can be beneficial. Additionally, MVA-based vaccines can deliver multiple heterologous antigens and allow for simultaneous induction of humoral and cellular immunity.
  • MVA vectors useful for the application can be prepared using methods known in the art, such as those described in WO/2002/042480 and WO/2002/24224, the relevant disclosures of which are incorporated herein by references.
  • the MVA vector(s) comprise a nucleic acid that encodes one or more antigenic proteins selected from the group consisting of HBV core antigen, HBV pol antigen, and a HBV core-HB V pol fusion antigen.
  • the HBV antigen protein may be inserted into one or more intergenic regions (IGR) of the MVA.
  • the IGR is selected from IGR07/08, IGR 44/45, IGR 64/65, IGR 88/89, IGR 136/137, and IGR 148/149.
  • less than 5, 4, 3, or 2 IGRs of the recombinant MVA comprise heterologous nucleotide sequences encoding antigenic determinants of a HBV core antigen and/or a HBV pol antigen.
  • heterologous nucleotide sequences may, additionally or alternatively, be inserted into one or more of the naturally occurring deletion sites, in particular into the main deletion sites I, II, III, IV, V, or VI of the MVA genome.
  • less than 5, 4, 3, or 2 of the naturally occurring deletion sites of the recombinant MVA comprise heterologous nucleotide sequences encoding antigenic determinants of a HBV core antigen and/or a HBV pol antigen.
  • the number of insertion sites of MVA comprising heterologous nucleotide sequences encoding antigenic determinants of a HBV protein can be 1, 2, 3, 4, 5, 6, 7, or more.
  • the heterologous nucleotide sequences are inserted into 4, 3, 2, or fewer insertion sites.
  • two insertion sites are used.
  • three insertion sites are used.
  • the recombinant MVA comprises at least 2, 3, 4, 5, 6, or 7 genes inserted into 2 or 3 insertion sites.
  • the recombinant MVA viruses provided herein can be generated by routine methods known in the art. Methods to obtain recombinant poxviruses or to insert exogenous coding sequences into a poxviral genome are well known to the person skilled in the art. For example, methods for standard molecular biology techniques such as cloning of DNA, DNA and RNA isolation, Western blot analysis, RT-PCR and PCR amplification techniques are described in Molecular Cloning, A laboratory Manual (2nd Ed.) (J. Sambrook et al, Cold Spring Harbor Laboratory Press (1989)), and techniques for the handling and manipulation of viruses are described in Virology Methods Manual (B.W.J. Mahy et al. (eds.), Academic Press (1996)). Similarly, techniques and know-how for the handling, manipulation and genetic engineering of MV A are described in
  • the DNA sequence to be inserted into the virus can be placed into an E. coli plasmid construct into which DNA homologous to a section of DNA of the MVA has been inserted.
  • the DNA sequence to be inserted can be ligated to a promoter.
  • the promoter-gene linkage can be positioned in the plasmid construct so that the promoter-gene linkage is flanked on both ends by DNA homologous to a DNA sequence flanking a region of MVA DNA containing a non-essential locus.
  • the resulting plasmid construct can be amplified by propagation within E. coli bacteria and isolated.
  • the isolated plasmid containing the DNA gene sequence to be inserted can be transfected into a cell culture, e.g., of chicken embryo fibroblasts (CEFs), at the same time the culture is infected with MVA. Recombination between homologous MVA DNA in the plasmid and the viral genome, respectively, can generate an MVA modified by the presence of foreign DNA sequences.
  • CEFs chicken embryo fibroblasts
  • a cell of a suitable cell culture as, e.g., CEF cells can be infected with a poxvirus.
  • the infected cell can be, subsequently, transfected with a first plasmid vector comprising a foreign or heterologous gene or genes, preferably under the transcriptional control of a poxvirus expression control element.
  • the plasmid vector also comprises sequences capable of directing the insertion of the exogenous sequence into a selected part of the poxviral genome.
  • the plasmid vector also contains a cassette comprising a marker and/or selection gene operably linked to a poxviral promoter.
  • Suitable marker or selection genes are, e.g., the genes encoding the green fluorescent protein, b- galactosidase, neomycin-phosphoribosyltransferase or other markers.
  • the use of selection or marker cassettes simplifies the identification and isolation of the generated recombinant poxvirus.
  • a recombinant poxvirus can also be identified by PCR technology. Subsequently, a further cell can be infected with the recombinant poxvirus obtained as described above and transfected with a second vector comprising a second foreign or heterologous gene or genes.
  • the second vector also differs in the poxvirus-homologous sequences directing the integration of the second foreign gene or genes into the genome of the poxvirus.
  • the recombinant virus comprising two or more foreign or heterologous genes can be isolated.
  • the steps of infection and transfection can be repeated by using the recombinant virus isolated in previous steps for infection and by using a further vector comprising a further foreign gene or genes for transfection.
  • a suitable cell can at first be transfected by the plasmid vector comprising the foreign gene and, then, infected with the poxvirus.
  • a suitable cell can at first be transfected by the plasmid vector comprising the foreign gene and, then, infected with the poxvirus.
  • a third alternative is ligation of DNA genome and foreign sequences in vitro and reconstitution of the recombined vaccinia virus DNA genome using a helper virus.
  • a fourth alternative is homologous recombination in E.coli or another bacterial species between a vaccinia virus genome, such as MV A, cloned as a bacterial artificial chromosome (BAC) and a linear foreign sequence flanked with DNA sequences homologous to sequences flanking the desired site of integration in the vaccinia virus genome.
  • MV A vaccinia virus genome
  • BAC bacterial artificial chromosome
  • the heterologous HBV gene (e.g., a HBV core antigen, a HBV pol antigen, and/or a HBV core-HBV-pol fusion protein) may be under the control of (i.e., operably linked to) one or more poxvirus promoters.
  • the poxvirus promoter is a Pr7.5 promoter, a hybrid early/late promoter, or a PrS promoter, a PrS5E promoter, a synthetic or natural early or late promoter, or a cowpox virus ATI promoter.
  • the application also relates to compositions, immunogenic combinations, more particularly kits, and vaccines comprising one or more HBV antigens, polynucleotides, and/or vectors encoding one more HBV antigens according to the application.
  • compositions, immunogenic combinations, more particularly kits, and vaccines comprising one or more HBV antigens, polynucleotides, and/or vectors encoding one more HBV antigens according to the application.
  • Any of the HBV antigens, polynucleotides (including RNA and DNA), and/or vectors of the application described herein can be used in the compositions, immunogenic combinations or kits, and vaccines of the application.
  • the application provides a composition comprising an isolated or non-naturally occurring nucleic acid molecule (DNA or RNA) encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2 or a HBV polymerase antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, a vector comprising the isolated or non-naturally occurring nucleic acid molecule, and/or an isolated or non-naturally occurring polypeptide encoded by the isolated or non-naturally occurring nucleic acid molecule.
  • DNA or RNA isolated or non-naturally occurring nucleic acid molecule
  • HBV polymerase antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4
  • a vector comprising the isolated or non-naturally occurring nucleic acid molecule, and/or an isolated or non-naturally occurring polypeptide encoded by the isolated or non-naturally occurring nucleic acid molecule.
  • a composition comprises an isolated or non-naturally occurring nucleic acid molecule (DNA or RNA) encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2, preferably 100% identical to SEQ ID NO: 2.
  • a composition comprises an isolated or non-naturally occurring nucleic acid molecule (DNA or RNA) encoding a HBV pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, preferably 100% identical to SEQ ID NO: 4.
  • composition comprises an isolated or non-naturally occurring nucleic acid molecule (DNA or RNA) comprising a
  • polynucleotide sequence encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2, preferably 100% identical to SEQ ID NO: 2; and an isolated or non-naturally occurring nucleic acid molecule (DNA or RNA) comprising a polynucleotide sequence encoding a HBV pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, preferably 100% identical to SEQ ID NO: 4.
  • the coding sequences for the truncated HBV core antigen and the HBV Pol antigen can be present in the same isolated or non-naturally occurring nucleic acid molecule (DNA or RNA), or in two different isolated or non-naturally occurring nucleic acid molecules (DNA or RNA).
  • a composition comprises a viral vector comprising a polynucleotide encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2, preferably 100% identical to SEQ ID NO: 2.
  • a composition comprises a viral vector comprising a polynucleotide encoding a HBV pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, preferably 100% identical to SEQ ID NO: 4.
  • a composition comprises a viral vector comprising a polynucleotide encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2, preferably 100% identical to SEQ ID NO: 2; and a viral vector comprising a polynucleotide encoding a HBV pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, preferably 100% identical to SEQ ID NO: 4.
  • the vector comprising the coding sequence for the truncated HBV core antigen and the vector comprising the coding sequence for the HBV pol antigen can be the same vector, or two different vectors.
  • a composition comprises a viral vector comprising a polynucleotide encoding a fusion protein comprising a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2, preferably 100% identical to SEQ ID NO: 2, operably linked to a HBV Pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:
  • the fusion protein further comprises a linker that operably links the truncated HBV core antigen to the HBV Pol antigen, or vice versa.
  • the linker has the amino acid sequence of (AlaGly)n, wherein n is an integer of 2 to 5.
  • a composition comprises an isolated or non-naturally occurring truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2, preferably 100% identical to SEQ ID NO: 2.
  • a composition comprises an isolated or non-naturally occurring HBV Pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, preferably 100% identical to SEQ ID NO: 4.
  • a composition comprises an isolated or non-naturally occurring truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2, preferably 100% identical to SEQ ID NO: 2; and an isolated or non-naturally occurring HBV Pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, preferably 100% identical to SEQ ID NO: 4.
  • a composition comprises an isolated or non-naturally occurring fusion protein comprising a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2, preferably 100% identical to SEQ ID NO: 2, operably linked to a HBV Pol antigen comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, preferably 100% identical to SEQ ID NO: 4, or vice versa.
  • the fusion protein further comprises a linker that operably links the truncated HBV core antigen to the HBV Pol antigen, or vice versa.
  • the linker has the amino acid sequence of
  • n is an integer of 2 to 5.
  • the application relates to an immunogenic combination or a kit comprising polynucleotides expressing a truncated HBV core antigen and an HBV pol antigen according to embodiments of the application.
  • Any polynucleotides and/or vectors encoding HBV core and pol antigens of the application described herein can be used in the immunogenic combinations or kits of the application.
  • the polynucleotides in a vaccine combination or kit can be linked or separate, such that the HBV antigens expressed from such polynucleotides are fused together or produced as separate proteins, whether expressed from the same or different polynucleotides.
  • the first and second polynucleotides are present in separate viral vectors used in combination either in the same or separate compositions, such that the expressed proteins are also separate proteins, but used in combination.
  • the HBV antigens encoded by the first and second polynucleotides can be expressed from the same viral vector, such that an HBV core-pol fusion antigen is produced.
  • the core and pol antigens can be joined or fused together by a short linker.
  • the HBV antigens encoded by the first and second polynucleotides can be expressed independently from a single vector using a using a ribosomal slippage site (also known as cis-hydrolase site) between the core and pol antigen coding sequences.
  • a ribosomal slippage site also known as cis-hydrolase site
  • This strategy results in a bicistronic expression vector in which individual core and pol antigens are produced from a single mRNA transcript.
  • the core and pol antigens produced from such a bicistronic expression vector can have additional N or C-terminal residues, depending upon the ordering of the coding sequences on the mRNA transcript.
  • ribosomal slippage sites examples include, but are not limited to, the FA2 slippage site from foot- and-mouth disease virus (FMDV).
  • FMDV foot- and-mouth disease virus
  • HBV antigens encoded by the first and second polynucleotides can be expressed independently from two separate vectors, one encoding the HBV core antigen and one encoding the HBV pol antigen.
  • the first and second polynucleotides are present in separate viral vectors.
  • the separate vectors are present in the same composition.
  • an immunogenic combination or kit comprises: a first vector, preferably a DNA plasmid or a viral vector, comprising a polynucleotide encoding a truncated HBV core antigen consisting of an amino acid sequence that is at least 90% identical to SEQ ID NO: 2, preferably 100% identical to SEQ ID NO: 2; and a second vector, preferably a DNA plasmid or a viral vector, comprising a polynucleotide encoding a HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO: 4, preferably 100% identical to SEQ ID NO: 4.
  • the first vector is a first DNA plasmid and the second vector is a second DNA plasmid.
  • Each of the first and second DNA plasmids comprises an origin of replication, preferably a pUC ORI of SEQ ID NO: 21, and an antibiotic resistance cassette, preferably comprising a codon optimized Kan r (Kanamycin resistance) gene having a polynucleotide sequence that is at least 90% identical to SEQ ID NO: 22, preferably under control of a bla promoter, for instance the bla promoter shown in SEQ ID NO: 24.
  • Kan r Kanamycin resistance
  • Each of the first and second DNA plasmids independently further comprises at least one of a promoter sequence, enhancer sequence, and a polynucleotide sequence encoding a signal peptide sequence operably linked to the first polynucleotide sequence or the second polynucleotide sequence.
  • each of the first and second DNA plasmids comprises an upstream sequence operably linked to the first polynucleotide or the second polynucleotide, wherein the upstream sequence comprises, from 5’ end to 3’ end, a promoter sequence of SEQ ID NO: 7, an enhancer sequence of SEQ ID NO: 8, and a polynucleotide sequence encoding a signal peptide sequence having the amino acid sequence of SEQ ID NO: 6.
  • Each of the first and second DNA plasmids can also comprise a polyadenylation signal located downstream of the coding sequence of the HBV antigen, such as the bGH polyadenylation signal of SEQ ID NO: 9.
  • the first vector is a first viral vector and the second vector is a second viral vector.
  • each of the first and second viral vector is an adenoviral vector, more preferably an Ad26 or Ad35 vector, comprising an expression cassette including the polynucleotide encoding the HBV pol antigen or the truncated HBV core antigen of the application; an upstream sequence operably linked to the polynucleotide encoding the HBV antigen comprising, from 5’ end to 3’ end, a promoter sequence, preferably a CMV promoter sequence of SEQ ID NO: 7, an enhancer sequence, preferably an ApoAI gene fragment sequence of SEQ ID NO: 15 or a triple enhancer sequence of SEQ ID NO: 8, and a polynucleotide sequence encoding a signal peptide sequence, preferably a cystatin S signal having the amino acid sequence of SEQ ID NO: 6 or an immunoglobulin secretion signal having the amino acid sequence
  • the first vector is a first viral vector and the second vector is a second viral vector.
  • each of the first and second viral vector is a MVA vector comprising an expression cassette including the polynucleotide encoding the HBV pol antigen and/or the truncated HBV core antigen of the application; an upstream sequence operably linked to the polynucleotide encoding the HBV antigen comprising, from 5’ end to 3’ end, a promoter sequence, preferably a PrMVAl3.5 long promoter sequence of SEQ ID NO: 25 or a PrHyb promoter sequence of SEQ ID NO: 26, and a polynucleotide sequence encoding a signal peptide sequence, preferably a cystatin S signal having the amino acid sequence of SEQ ID NO: 6 or an immunoglobulin secretion signal having the amino acid sequence of SEQ ID NO: 11; and a downstream sequence operably linked to the polynucleotide
  • a vaccine combination comprising (a) a first composition comprising an immunologically effective amount of an adenovirus vector comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:4, wherein the HBV polymerase antigen does not have reverse transcriptase activity and RNase H activity; and (b) a second composition comprising an
  • a Modified Vaccinia Ankara (MVA) vector comprising a second polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO: 4, wherein the HBV polymerase antigen does not have reverse transcriptase activity and RNase H activity; wherein the first composition is administered to the human subject for priming the immune response, and the second composition is administered to the human subject one or more times for boosting the immune response.
  • VVA Modified Vaccinia Ankara
  • a vaccine combination comprising (a) a first composition comprising an immunologically effective amount of a Modified Vaccinia Ankara (MV A) vector comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:4, wherein the HBV polymerase antigen does not have reverse transcriptase activity and RNase H activity; and (b) a second composition comprising an immunologically effective amount of an adenovirus vector comprising a second polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO: 4, wherein the HBV polymerase antigen does not have reverse transcriptase activity and RNase H activity; wherein the first composition is administered to the human subject for priming the immune response, and the second composition is administered to the human subject one or more times for boosting the immune response.
  • MV A Modified Vaccinia Ankara
  • the combination comprises a first viral vector and a second viral vector
  • the amount of each of the first and second vectors is not particularly limited.
  • the first viral vector and the second viral vector can be present in a ratio of 10: 1 to 1 : 10, by weight, such as 10: 1, 9: 1, 8: 1, 7: 1, 6: 1, 5: 1, 4: 1, 3: 1, 2: 1, 1 : 1, 1 :2, 1 :3, 1 :4, 1 :5, 1 :6, 1 :7, 1 :8, 1 :9, or 1 : 10, by weight.
  • the first and second viral vectors are present in a ratio of 1 : 1 , by weight.
  • compositions and immunogenic combinations of the application can comprise additional polynucleotides or vectors encoding additional HBV antigens and/or additional HBV antigens or immunogenic fragments thereof. However, in particular embodiments, the compositions and immunogenic combinations of the application do not comprise certain antigens.
  • composition or immunogenic combination or kit of the application does not comprise a HBsAg or a polynucleotide sequence encoding the HBsAg.
  • a composition or immunogenic combination or kit of the application does not comprise a HBV L protein or a polynucleotide sequence encoding the HBV L protein.
  • composition or immunogenic combination of the application does not comprise a HBV envelope protein or a polynucleotide sequence encoding the HBV envelope protein.
  • compositions and immunogenic combinations of the application can also comprise a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier is non-toxic and should not interfere with the efficacy of the active ingredient.
  • Pharmaceutically acceptable carriers can include one or more excipients such as binders, disintegrants, swelling agents, suspending agents, emulsifying agents, wetting agents, lubricants, flavorants, sweeteners, preservatives, dyes, solubilizers and coatings.
  • excipients such as binders, disintegrants, swelling agents, suspending agents, emulsifying agents, wetting agents, lubricants, flavorants, sweeteners, preservatives, dyes, solubilizers and coatings.
  • suitable carriers and additives include water, glycols, oils, alcohols, preservatives, coloring agents and the like.
  • suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like.
  • the aqueous solution/suspension can comprise water, glycols, oils, emollients, stabilizers, wetting agents, preservatives, aromatics, flavors, and the like as suitable carriers and additives.
  • compositions and immunogenic combinations of the application can be formulated in any matter suitable for administration to a subject to facilitate
  • compositions of the application can also be formulated for other routes of administration including transmucosal, ocular, rectal, long acting implantation, sublingual administration, under the tongue, from oral mucosa bypassing the portal circulation, inhalation, or intranasal.
  • compositions and immunogenic combinations of the application are formulated for parental injection, preferably subcutaneous, intradermal injection, or intramuscular injection, more preferably intramuscular injection.
  • compositions and immunogenic combinations for administration will typically comprise a buffered solution in a pharmaceutically acceptable carrier, e.g., an aqueous carrier such as buffered saline and the like, e.g., phosphate buffered saline (PBS).
  • a pharmaceutically acceptable carrier e.g., an aqueous carrier such as buffered saline and the like, e.g., phosphate buffered saline (PBS).
  • PBS phosphate buffered saline
  • a composition or immunogenic combination of the application comprising plasmid DNA can contain phosphate buffered saline (PBS) as the pharmaceutically acceptable carrier.
  • the plasmid DNA can be present in a concentration of, e.g., 0.5 mg/mL to 5 mg/mL, such as 0.5 mg/mL 1, mg/mL, 2 mg/mL, 3 mg/mL, 4 mg/mL, or 5 mg/mL, preferably at 1 mg/mL.
  • compositions and immunogenic combinations of the application can be formulated as a vaccine (also referred to as an“immunogenic composition”) according to methods well known in the art.
  • a vaccine also referred to as an“immunogenic composition”
  • Such compositions can include adjuvants to enhance immune responses.
  • the optimal ratios of each component in the formulation can be determined by techniques well known to those skilled in the art in view of the present disclosure.
  • an adjuvant is included in a composition or immunogenic combination of the application, or co-administered with a composition or immunogenic combination of the application.
  • Use of an adjuvant is optional, and may further enhance immune responses when the composition is used for vaccination purposes.
  • Adjuvants suitable for co-administration or inclusion in compositions in accordance with the application should preferably be ones that are potentially safe, well tolerated and effective in humans.
  • An adjuvant can be a small molecule or antibody including, but not limited to, immune checkpoint inhibitors (e.g., anti-PDl, anti-RIM-3, etc.), toll-like receptor inhibitors, RIG-l inhibitors, IL-15 superagonists (Altor Bioscience), mutant IRF3 and IRF7 genetic adjuvants, STING agonists (Aduro), FLT3L genetic adjuvant, IL-12 genetic adjuvant, and IL-7-hyFc.
  • immune checkpoint inhibitors e.g., anti-PDl, anti-RIM-3, etc.
  • toll-like receptor inhibitors e.g., RIG-l inhibitors
  • IL-15 superagonists e.g., Altor Bioscience
  • mutant IRF3 and IRF7 genetic adjuvants e.g., STING agonists (Aduro)
  • FLT3L genetic adjuvant e.g., IL-12 genetic adjuvant
  • Embodiments of the application also relate to methods of making compositions and immunogenic combinations of the application.
  • a method of producing a composition or immunogenic combination comprises mixing an isolated polynucleotide encoding an HBV antigen, vector, and/or polypeptide of the application with one or more pharmaceutically acceptable carriers.
  • the application relates to a method of inducing an immune response against hepatitis B virus (HBV) in a subject in need thereof, comprising administering to the subject an immunologically effective amount of a composition or immunogenic composition of the application.
  • HBV hepatitis B virus
  • the application provides an improved method of priming and boosting an immune response to a HBV antigenic protein or immunogenic polypeptide thereof in a human subject using an MVA vector in combination with an adenoviral vector.
  • a method of enhancing an immune response in a human subject comprises:
  • a method of enhancing an immune response in a human subject comprises: a. administering to the human subject a first composition comprising an immunologically effective amount of a MVA vector of the application; and
  • a method of enhancing an immune response in a human subject comprises:
  • a method of enhancing an immune response in a human subject comprises:
  • a second composition comprising an immunologically effective amount of a first plasmid comprising a first non-naturally occurring nucleic acid comprising a first polynucleotide sequence encoding an HBV pol antigen of the application, and an immunologically effective amount of a second plasmid comprising a second non-naturally occurring nucleic acid comprising a second polynucleotide sequence encoding a truncated HBV core antigen of the application;
  • the first composition is administered to the human subject in need thereof to prime the immune response
  • the second composition is administered to the human subject in need thereof to boost the immune response.
  • Priming and boosting the immune response can, for example, enhance the immune response.
  • the enhanced immune response comprises an enhanced antibody response against the HBV antigenic protein in the human subject.
  • the enhanced immune response further comprises an enhanced CD4+ response or an enhanced CD8+ T cell response against the HBV antigenic protein in the human subject.
  • the enhanced CD4+ T cell response generated by a method according to an embodiment of the application can be, for example, an increase or induction of a dominant CD4+ T cell response against the HBV antigenic protein, and/or an increase or induction of polyfunctional CD4+ T cells specific to the HBV antigenic protein in the human subject.
  • the polyfunctional CD4+ T cells express more than one cytokine, such as two or more of IFN-gamma, IL-2 and TNF-alpha.
  • the enhanced CD8+ T cell response generated by a method according to an embodiment of the application can be, for example, an increase or induction of polyfunctional CD8+ T cells specific to the HBV antigenic protein in the human subject.
  • the enhanced immune response resulting from a method according to an embodiment of the application comprises an enhanced CD4+ T cell response, an enhanced antibody response and an enhanced CD8+ T cell response, against the HBV antigenic protein in the human subject.
  • the term“infection” refers to the invasion of a host by a disease causing agent.
  • a disease causing agent is considered to be“infectious” when it is capable of invading a host, and replicating or propagating within the host.
  • infectious agents include viruses, e.g., HBV and certain species of adenovirus, prions, bacteria, fungi, protozoa and the like.
  • HBV infection specifically refers to invasion of a host organism, such as cells and tissues of the host organism, by HBV.
  • “inducing an immune response” when used with reference to the methods described herein encompasses causing a desired immune response or effect in a subject in need thereof against HBV or an HBV infection. “Inducing an immune response” also encompasses providing a therapeutic immunity for treating against a pathogenic agent, i.e., HBV.
  • a pathogenic agent i.e., HBV.
  • the term“therapeutic immunity” or“therapeutic immune response” means that the HBV-infected vaccinated subject is able to control an infection with the pathogenic agent, i.e., HBV, against which the vaccination was done.
  • “inducing an immune response” means producing an immunity in a subject in need thereof, e.g., to provide a therapeutic effect against a disease, such as HBV infection.
  • “inducing an immune response” refers to causing or improving cellular immunity, e.g., T cell response, against HBV.
  • “inducing an immune response” refers to causing or improving a humoral immune response against HBV.
  • “inducing an immune response” refers to causing or improving a cellular and a humoral immune response against HBV.
  • compositions and immunogenic combinations according to embodiments of the application will have a therapeutic aim to generate an immune response against HBV after HBV infection or development of symptoms characteristic of HBV infection, i.e., for therapeutic vaccination.
  • an immunogenically effective amount” or“immunologically effective amount” means an amount of a composition, polynucleotide, vector, or antigen sufficient to induce a desired immune effect or immune response in a subject in need thereof.
  • an immunologically effective amount means an amount sufficient to induce an immune response in a subject in need thereof.
  • an immunologically effective amount means an amount sufficient to produce immunity in a subject in need thereof, e.g., provide a therapeutic effect against a disease such as HBV infection.
  • An immunologically effective amount can vary depending upon a variety of factors, such as the physical condition of the subject, age, weight, health, etc.; the particular application, e.g., providing protective immunity or therapeutic immunity; and the particular disease, e.g., viral infection, for which immunity is desired.
  • An immunologically effective amount can readily be determined by one of ordinary skill in the art in view of the present disclosure.
  • an immunologically effective amount refers to the amount of a composition or immunogenic combination which is sufficient to achieve one, two, three, four, or more of the following effects: (i) reduce or ameliorate the severity of an HBV infection or a symptom associated therewith; (ii) reduce the duration of an HBV infection or symptom associated therewith; (iii) prevent the progression of an HBV infection or symptom associated therewith; (iv) cause regression of an HBV infection or symptom associated therewith; (v) prevent the development or onset of an HBV infection, or symptom associated therewith; (vi) prevent the recurrence of an HBV infection or symptom associated therewith; (vii) reduce hospitalization of a subject having an HBV infection; (viii) reduce hospitalization length of a subject having an HBV infection; (ix) increase the survival of a subject with an HBV infection; (x) eliminate an HBV infection in a subject; (xi) inhibit or reduce HBV replication in a subject; and
  • an immunologically effective amount is an amount sufficient to reduce HBsAg levels consistent with evolution to clinical seroconversion; achieve sustained HBsAg clearance associated with reduction of infected hepatocytes by a subject’s immune system; induce HBV-antigen specific activated T-cell populations; and/or achieve persistent loss of HBsAg within 12 months.
  • a target index include lower HBsAg below a threshold of 500 copies of HBsAg IU and/or higher CD 8 counts.
  • an immunologically effective amount when used with reference to a viral vector can range from about 1 X 10 7 viral particles per dose to about 1 X 10 12 viral particles per dose.
  • An immunologically effective amount can be about 1 X
  • An immunologically effective amount can be from one vector or from multiple vectors.
  • An immunologically effective amount can be administered in a single composition, or in multiple compositions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 compositions (e.g., tablets, capsules or injectables), wherein the administration of the multiple capsules or injections collectively provides a subject with an immunologically effective amount. It is also possible to administer an immunologically effective amount to a subject, and
  • prime-boost regimen subsequently administer another dose of an immunologically effective amount to the same subject, in a so-called prime-boost regimen.
  • This general concept of a prime-boost regimen is well known to the skilled person in the vaccine field. Further booster administrations can optionally be added to the regimen, as needed.
  • an immunogenic combination comprising two viral vectors, e.g., a first viral vector encoding an HBV core antigen and second viral vector encoding an HBV pol antigen can be administered to a subject by mixing both viral vectors and delivering the mixture to a single anatomic site.
  • the first viral vector and the second viral vector can be administered in a ratio of 10: 1 to 1 : 10, by weight, such as 10: 1, 9: 1, 8: 1, 7: 1, 6: 1, 5: 1, 4: 1, 3: 1, 2: 1, 1 : 1, 1 :2, 1 :3, 1 :4, 1 :5, 1 :6, 1 :7, 1 :8, 1 :9, or 1 : 10, by weight.
  • the first and second viral vectors are administered in a ratio of 1 : 1, by weight.
  • a subject to be treated according to the methods of the application is an HBV-infected subject, particular a subject having chronic HBV infection.
  • Acute HBV infection is characterized by an efficient activation of the innate immune system complemented with a subsequent broad adaptive response (e.g., HBV- specific T-cells, neutralizing antibodies), which usually results in successful suppression of replication or removal of infected hepatocytes.
  • HBV-specific T-cells, neutralizing antibodies e.g., HBV- specific T-cells, neutralizing antibodies
  • HBV envelope proteins are produced in abundance and can be released in sub-viral particles in 1, 000-fold excess to infectious virus.
  • Chronic HBV infection is described in phases characterized by viral load, liver enzyme levels (necroinflammatory activity), HBeAg, or HBsAg load or presence of antibodies to these antigens.
  • cccDNA levels stay relatively constant at approximately 10 to 50 copies per cell, even though viremia can vary considerably. The persistence of the cccDNA species leads to chronicity.
  • the phases of chronic HBV infection include: (i) the immune-tolerant phase characterized by high viral load and normal or minimally elevated liver enzymes; (ii) the immune activation HBeAg-positive phase in which lower or declining levels of viral replication with significantly elevated liver enzymes are observed; (iii) the inactive HBsAg carrier phase, which is a low replicative state with low viral loads and normal liver enzyme levels in the serum that may follow HBeAg seroconversion; and (iv) the HBeAg-negative phase in which viral replication occurs periodically (reactivation) with concomitant fluctuations in liver enzyme levels, mutations in the pre-core and/or basal core promoter are common, such that HBeAg is not produced by the infected cell.
  • chronic HBV infection refers to a subject having the detectable presence of HBV for more than 6 months.
  • a subject having a chronic HBV infection can be in any phase of chronic HBV infection.
  • a chronic HBV infection referred to herein follows the definition published by the Centers for Disease Control and Prevention (CDC), according to which a chronic HBV infection is characterized by the following laboratory criteria: (i) negative for IgM antibodies to hepatitis B core antigen (IgM anti-HBc) and positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), or nucleic acid test for hepatitis B virus DNA, or (ii) positive for HBsAg or nucleic acid test for HBV DNA, or positive for HBeAg two times at least 6 months apart.
  • IgM anti-HBc hepatitis B core antigen
  • HBsAg hepatitis B surface antigen
  • HBeAg he
  • an immunogenically effective amount refers to the amount of a composition or immunogenic combination which is sufficient to treat chronic HBV infection.
  • a subject having chronic HBV infection is undergoing nucleoside analog (NUC) treatment, and is NUC-suppressed.
  • NUC- suppressed refers to a subject having an undetectable viral level of HBV and stable alanine aminotransferase (ALT) levels for at least six months.
  • nucleoside/nucleotide analog treatment include HBV polymerase inhibitors, such as entacavir and tenofovir.
  • a subject having chronic HBV infection does not have advanced hepatic fibrosis or cirrhosis. Such subject would typically have a
  • the METAVIR score is a scoring system that is commonly used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy of patients with hepatitis B.
  • the scoring system assigns two standardized numbers: one reflecting the degree of inflammation and one reflecting the degree of fibrosis.
  • an immunogenically effective amount is an amount sufficient to achieve persistent loss of HBsAg within 12 months and significant decrease in clinical disease (e.g., cirrhosis, hepatocellular carcinoma, etc.).
  • Methods according to embodiments of the application further comprise administering to the subject in need thereof another immunogenic agent (such as another HBV antigen or other antigen) or another anti-HBV agent (such as a nucleoside analog or other anti-HBV agent) in combination with a composition of the application.
  • another immunogenic agent such as another HBV antigen or other antigen
  • another anti-HBV agent such as a nucleoside analog or other anti-HBV agent
  • compositions and immunogenic combinations of the application can be administered to a subject by any method known in the art in view of the present disclosure, including, but not limited to, parenteral administration (e.g., intramuscular, subcutaneous, intravenous, or intradermal injection), oral administration, transdermal administration, and nasal administration.
  • parenteral administration e.g., intramuscular, subcutaneous, intravenous, or intradermal injection
  • oral administration e.g., oral administration, transdermal administration, and nasal administration.
  • compositions and immunogenic combinations are administered parenterally (e.g., by intramuscular injection or intradermal injection) or transdermally.
  • administration can be by injection through the skin, e.g., intramuscular or intradermal injection, preferably intramuscular injection.
  • Intramuscular injection can be combined with electroporation, i.e., application of an electric field to facilitate delivery of the DNA plasmids to cells.
  • electroporation i.e., application of an electric field to facilitate delivery of the DNA plasmids to cells.
  • electroporation refers to the use of a transmembrane electric field pulse to induce microscopic pathways (pores) in a bio-membrane.
  • transfection efficiency and immune response are significantly improved (e.g., up to 1,000 fold and 100 fold respectively) with intradermal or intramuscular electroporation, in comparison to conventional injection.
  • electroporation is combined with intramuscular injection.
  • electroporation is also possible to combine electroporation with other forms of parenteral administration, e.g., intradermal injection, subcutaneous injection, etc.
  • Administration of a composition, immunogenic combination or vaccine of the application via electroporation can be accomplished using electroporation devices that can be configured to deliver to a desired tissue of a mammal a pulse of energy effective to cause reversible pores to form in cell membranes.
  • the electroporation device can include an electroporation component and an electrode assembly or handle assembly.
  • the electroporation component can include one or more of the following components of electroporation devices: controller, current waveform generator, impedance tester, waveform logger, input element, status reporting element, communication port, memory component, power source, and power switch. Electroporation can be accomplished using an in vivo electroporation device. Examples of electroporation devices and
  • electroporation methods that can facilitate delivery of compositions and immunogenic combinations of the application, particularly those comprising DNA plasmids, include CELLECTRA® (Inovio Pharmaceuticals, Blue Bell, PA), Elgen electroporator (Inovio Pharmaceuticals, Inc.) Tri-GridTM delivery system (Ichor Medical Systems, Inc., San Diego, CA 92121) and those described in U.S. Patent No. 7,664,545, U.S. Patent No. 8,209,006, U.S. Patent No. 9,452,285, U.S. Patent No. 5,273,525, U.S. Patent No.
  • the method of administration is transdermal.
  • Transdermal administration can be combined with epidermal skin abrasion to facilitate delivery of the DNA plasmids to cells.
  • a dermatological patch can be used for epidermal skin abrasion. Upon removal of the dermatological patch, the composition or immunogenic combination can be deposited on the abraised skin.
  • Methods of delivery are not limited to the above described embodiments, and any means for intracellular delivery can be used.
  • Other methods of intracellular delivery contemplated by the methods of the application include, but are not limited to, liposome encapsulation, nanoparticles, etc.
  • a method of inducing an immune response against HBV further comprises administering an adjuvant.
  • adjuvant and “immune stimulant” are used interchangeably herein, and are defined as one or more substances that cause stimulation of the immune system.
  • an adjuvant is used to enhance an immune response to HBV antigens and antigenic HBV polypeptides of the application.
  • an adjuvant can be present in an immunogenic combination or composition of the application, or administered in a separate composition.
  • An adjuvant can be, e.g., a small molecule or an antibody.
  • adjuvants suitable for use in the application include, but are not limited to, immune checkpoint inhibitors (e.g., anti-PDl, anti-RIM-3, etc.), toll-like receptor inhibitors, RIG-l inhibitors, IL-15 superagonists (Altor Bioscience), mutant IRF3 and IRF7 genetic adjuvants, STING agonists (Aduro), FLT3L genetic adjuvant, IL-12 genetic adjuvant, and IL-7-hyFc.
  • immune checkpoint inhibitors e.g., anti-PDl, anti-RIM-3, etc.
  • toll-like receptor inhibitors e.g., RIG-l inhibitors
  • IL-15 superagonists e.g., IL-15 superagonists (Altor Bioscience)
  • mutant IRF3 and IRF7 genetic adjuvants e.g., STING agonists (Aduro)
  • FLT3L genetic adjuvant e.g., IL-12 genetic adjuvant
  • compositions and immunogenic combinations of the application can also be administered in combination with at least one other anti-HBV agent.
  • anti- HBV agents suitable for use with the application include, but are not limited to small molecules, antibodies, and/or CAR-T therapies that function as capsid inhibitors, TER inhibitors, cccDNA inhibitors, HBV polymerase inhibitors (e.g., entecavir and tenofovir), and/or immune checkpoint inhibitors, etc.
  • Such anti-HBV agents can be administered with the compositions and immunogenic combinations of the application simultaneously or sequentially.
  • Embodiments of the application also contemplate administering an
  • a composition or immunogenic combination of the application is a primer vaccine used for priming an immune response.
  • a composition or immunogenic combination of the application is a booster vaccine used for boosting an immune response.
  • the priming and boosting vaccines according to embodiments of the application can be used in the methods of the application described herein. This general concept of a prime-boost regimen is well known to the skilled person in the vaccine field.
  • compositions and immunogenic combinations of the application described herein can be used as priming and/or boosting vaccines for priming and/or boosting an immune response against HBV.
  • a composition or immunogenic combination of the application can be administered at least once for priming
  • composition or immunogenic combination can be re-administered for boosting immunization. Further booster administrations of the composition or vaccine combination can optionally be added to the regimen, as needed.
  • An adjuvant can be present in a composition of the application used for boosting immunization, present in a separate composition to be administered together with the composition or immunogenic combination of the application for the boosting immunization, or administered on its own as the boosting immunization. In those embodiments in which an adjuvant is included in the regimen, the adjuvant is preferably used for boosting immunization.
  • An illustrative and non-limiting example of a prime-boost regimen includes administering a single dose of an immunologically effective amount of a composition or immunogenic combination of the application to a subject to prime the immune response; and subsequently administering another dose of an immunologically effective amount of a composition or immunogenic combination of the application to boost the immune response, wherein the boosting immunization is first administered about one to twelve weeks (1 to 12), about two to twelve weeks (2 to 12), about two to ten weeks (2 to 10), about two to six weeks (2 to 6), preferably about four weeks after the priming
  • the immunization is initially administered, preferably about eight weeks after the priming immunization is initially administered.
  • the boosting immunization is administered at least one week after the priming immunization.
  • the boosting immunization is administered at least two weeks after the priming immunization.
  • kits comprising an immunogenic combination of the application.
  • a kit can comprise the first polynucleotide and the second
  • kits can comprise the first polynucleotide and the second polynucleotide in a single composition.
  • a kit can further comprise one or more adjuvants or immune stimulants, and/or other anti-HBV agents.
  • the ability to induce or stimulate an anti-HBV immune response upon administration in an animal or human organism can be evaluated either in vitro or in vivo using a variety of assays which are standard in the art.
  • assays which are standard in the art.
  • Measurement of cellular immunity can be performed by measurement of cytokine profiles secreted by activated effector cells including those derived from CD4+ and CD8+ T-cells (e.g.
  • IL-10 or IFN gamma-producing cells by ELISPOT
  • determination of the activation status of immune effector cells e.g. T cell proliferation assays by a classical [3H] thymidine uptake
  • assaying for antigen-specific T lymphocytes in a sensitized subject e.g. peptide-specific lysis in a cytotoxicity assay, etc.
  • the ability to stimulate a cellular and/or a humoral response can be determined by antibody binding and/or competition in binding (see for example Harlow, 1989, Antibodies, Cold Spring Harbor Press).
  • titers of antibodies produced in response to administration of a composition providing an immunogen can be measured by enzyme-linked immunosorbent assay (ELISA).
  • ELISA enzyme-linked immunosorbent assay
  • the immune responses can also be measured by neutralizing antibody assay, where a neutralization of a virus is defined as the loss of infectivity through reaction/inhibition/neutralization of the virus with specific antibody.
  • the immune response can further be measured by Antibody-Dependent Cellular Phagocytosis (ADCP) Assay.
  • ADCP Antibody-Dependent Cellular Phagocytosis
  • Embodiment 1 is a Modified Vaccinia Ankara (MV A) vector comprising a non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:4.
  • MV A Modified Vaccinia Ankara
  • Embodiment 2 is the MVA vector of embodiment 1, wherein the HBV polymerase antigen does not have reverse transcriptase activity and RNase H activity.
  • Embodiment 3 is the MVA vector of embodiment 1 or 2, wherein the HBV polymerase antigen is capable of inducing an immune response in a mammal against at least two HBV genotypes, preferably the HBV polymerase antigen is capable of inducing a T cell response in a mammal against at least HBV genotypes B, C, and D, and more preferably the HBV polymerase antigen is capable of inducing a CD8 T cell response in a human subject against at least HBV genotypes A, B, C, and D.
  • Embodiment 4 is the MVA vector of any one of embodiments 1-3, wherein the HBV polymerase antigen comprises the amino acid sequence of SEQ ID NO: 4.
  • Embodiment 5 is the MVA vector of any one of embodiments 1-4, further comprising a polynucleotide sequence encoding a signal sequence operably linked to the HBV polymerase antigen.
  • Embodiment 6 is the MVA vector of embodiment 5, wherein the signal sequence comprises the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 11, preferably the signal sequence is encoded by the polynucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 10.
  • Embodiment 7 is the MVA vector of any one of embodiments 1-6, wherein the first polynucleotide sequence is at least 90% identical to SEQ ID NO: 3.
  • Embodiment 8 is the MVA vector of embodiment 7, wherein the first polynucleotide sequence comprises the polynucleotide sequence of SEQ ID NO: 3.
  • Embodiment 9 is the MVA vector of any one of embodiments 1-8, further comprising a second polynucleotide sequence encoding a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2.
  • Embodiment 10 is the MVA vector of embodiment 9, wherein the second polynucleotide sequence is at least 90% identical to SEQ ID NO: 1.
  • Embodiment 11 is the MVA vector of embodiment 10, wherein the second polynucleotide sequence comprises the polynucleotide sequence of SEQ ID NO: 1.
  • Embodiment 12 is the MVA vector of any one of embodiments 9-11, wherein the second polynucleotide sequence further comprises a polynucleotide sequence encoding a signal sequence operably linked to the truncated HBV core antigen.
  • Embodiment 13 is the MVA vector of embodiment 12, wherein the signal sequence comprises the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 11, preferably the signal sequence is encoded by the polynucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 10.
  • Embodiment 14 is the MVA vector of any one of embodiments 9-13, wherein the first and second polynucleotide sequences encode a fusion protein comprising the truncated HBV core antigen operably linked to the HBV polymerase antigen.
  • Embodiment 15 is the MVA vector of embodiment 14, wherein the fusion protein comprises the truncated HBV core antigen operably linked to the HBV
  • Embodiment 16 is the MVA vector of embodiment 15, wherein the linker comprises the amino acid sequence of (AlaGly)n, and n is an integer of 2 to 5, preferably the linker is encoded by a polynucleotide sequence comprising SEQ ID NO: 14.
  • Embodiment 17 is the MVA vector of embodiment 16, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 12.
  • Embodiment 18 is the MVA vector of any one of embodiments 14-17, wherein the fusion protein further comprises a signal sequence, preferably the signal sequence comprises the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 11, more preferably the signal sequence is encoded by the polynucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 10.
  • Embodiment 19 is the MVA vector of any one of embodiments 1-18 further comprising at least one promoter sequence, optionally one or more additional regulatory sequences, preferably the at least one promoter sequence comprises the polynucleotide sequence of SEQ ID NO: 25 and/or SEQ ID NO: 26, and the additional regulatory sequence is selected from the group consisting of an enhancer sequence of SEQ ID NO: 8 or SEQ ID NO: 15, and a polyadenylation signal sequence of SEQ ID NO: 9 or SEQ ID NO: 16.
  • Embodiment 20 is the MVA vector of any one of embodiments 1-19, wherein the non-naturally occurring nucleic acid molecule does not encode a HBV antigen selected from the group consisting of a Hepatitis B surface antigen (HBsAg), a HBV envelope (Env) antigen, and a HBV L protein antigen.
  • a HBV antigen selected from the group consisting of a Hepatitis B surface antigen (HBsAg), a HBV envelope (Env) antigen, and a HBV L protein antigen.
  • Embodiment 21 is an MVA vector comprising a first non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising the amino acid sequence of SEQ ID NO: 4, wherein the first polynucleotide sequence further encodes a signal sequence comprising the amino acid sequence of SEQ ID NO: 6, and wherein the first polynucleotide sequence further comprises a promoter sequence comprising the polynucleotide sequence of SEQ ID NO: 26, and a second non-naturally occurring nucleic acid molecule comprising a second polynucleotide sequence encoding a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2, wherein the second polynucleotide sequence further encodes a signal sequence comprising the amino acid sequence of SEQ ID NO: 11, and wherein the second polynucleotide sequence further comprises a promoter sequence comprising the polynucleot
  • Embodiment 22 is a composition comprising the MVA vector of any one of embodiments 1-21 and a pharmaceutically acceptable carrier.
  • Embodiment 23 is a method of enhancing an immune response in a human subject, the method comprising (a) administering to the human subject a first composition comprising an immunologically effective amount of an adenovirus vector comprising a non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:4; and (b) administering to the human subject a second composition comprising an immunologically effective amount of the MVA vector of any one of embodiments 1-21 ; to thereby obtain an enhanced immune response against the HBV antigen in the human subject.
  • Embodiment 24 is the method of embodiment 23, wherein the HBV polymerase antigen of the first composition does not have reverse transcriptase activity and RNase H activity.
  • Embodiment 25 is the method of embodiment 23 or 24, wherein the first composition is for priming the immune response and the second composition is for boosting the immune response.
  • Embodiment 26 is the method of any one of embodiments 23-25, wherein the HBV polymerase antigen of the first composition is capable of inducing an immune response in the human subject against at least two HBV genotypes, preferably the HBV polymerase antigen is capable of inducing a T cell response in the human subject against at least HBV genotypes B, C, and D, and more preferably the HBV polymerase antigen is capable of inducing a CD8 T cell response in the human subject against at least HBV genotypes A, B, C, and D.
  • the HBV polymerase antigen of the first composition is capable of inducing an immune response in the human subject against at least two HBV genotypes, preferably the HBV polymerase antigen is capable of inducing a T cell response in the human subject against at least HBV genotypes B, C, and D, and more preferably the HBV polymerase antigen is capable of inducing a CD8 T cell response in the human subject against at least HBV genotypes
  • Embodiment 27 is the method of any one of embodiments 23-26, wherein the HBV polymerase antigen of the first composition comprises the amino acid sequence of SEQ ID NO: 4.
  • Embodiment 28 is the method of any one of embodiments 23-27, further comprising a polynucleotide sequence encoding a signal sequence operably linked to the HBV polymerase antigen of the first composition.
  • Embodiment 29 is the method of embodiment 28, wherein the signal sequence comprises the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 11, preferably the signal sequence is encoded by the polynucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 10.
  • Embodiment 30 is the method of any one of embodiments 23-29, wherein the first polynucleotide sequence of the first composition is at least 90% identical to SEQ ID NO: 19.
  • Embodiment 31 is the method of embodiment 30, wherein the first polynucleotide sequence of the first composition comprises the polynucleotide sequence of SEQ ID NO: 19.
  • Embodiment 32 is the method of any one of embodiments 23-31, wherein the nucleic acid molecule of the adenovirus in the first composition further comprises a second polynucleotide sequence encoding a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2.
  • Embodiment 33 is the method of embodiment 32, wherein the second polynucleotide sequence of the first composition is at least 90% identical to SEQ ID NO: 17.
  • Embodiment 34 is the method of embodiment 33, wherein the second polynucleotide sequence of the first composition comprises the polynucleotide sequence of SEQ ID NO: 17.
  • Embodiment 35 is the method of any one of embodiments 32-34, wherein the first and second polynucleotide sequences of the first composition encode a fusion protein comprising the truncated HBV core antigen operably linked to the HBV polymerase antigen.
  • Embodiment 36 is the method of embodiment 35, wherein the fusion protein of the first composition comprises the truncated HBV core antigen operably linked to the HBV polymerase antigen via a linker.
  • Embodiment 37 is the method of embodiment 36, wherein the linker of the first composition comprises the amino acid sequence of (AlaGly)n, and n is an integer of 2 to 5, preferably the linker is encoded by a polynucleotide sequence comprising SEQ ID NO: 14.
  • Embodiment 38 is the method of embodiment 37, wherein the fusion protein of the first composition comprises the amino acid sequence of SEQ ID NO: 12.
  • Embodiment 39 is the method of any one of embodiments 35-38, wherein the fusion protein of the first composition further comprises a signal sequence, preferably the signal sequence comprises the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 11, more preferably the signal sequence is encoded by the polynucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 10.
  • Embodiment 40 is the method of any one of embodiments 23-39, wherein the non-naturally occurring nucleic acid molecule of the first composition further comprises a promoter sequence, optionally one or more additional regulatory sequences, preferably the promoter sequence comprises the polynucleotide sequence of SEQ ID NO: 7, and the additional regulatory sequence is selected from the group consisting of an enhancer sequences of SEQ ID NO: 8 or SEQ ID NO: 15, and a polyadenylation signal sequence of SEQ ID NO: 16.
  • Embodiment 41 is the method of any one of embodiments 23-40, wherein the non-naturally occurring nucleic acid molecule of the first composition does not encode a HBV antigen selected from the group consisting of a Hepatitis B surface antigen
  • HBV envelope (Env) antigen HBsAg
  • HBV L protein antigen HBsAg
  • Env HBV envelope
  • Embodiment 42 is the method of any one of claims 23-41, wherein the enhanced immune response comprises an enhanced antibody response against the HBV antigen in the human subject.
  • Embodiment 43 is the method of embodiment 42, wherein the enhanced immune response comprises an enhanced CD8+ T cell response against the HBV antigen in the human subject.
  • Embodiment 44 is the method of embodiment 42 or 43, wherein the enhanced immune response comprises an enhanced CD4+ T cell response against the HBV antigen in the human subject.
  • Embodiment 45 is the method of any one of embodiments 23-44, wherein the adenovirus vector is an rAd26 or rAd35 vector.
  • Embodiment 46 is the method of any one of embodiments 23-45, wherein step (b) is conducted 1-12 weeks after step (a).
  • Embodiment 47 is the method of any one of embodiments 23-45, wherein step (b) is conducted 2-12 weeks after step (a).
  • Embodiment 48 is the method of any one of embodiments 23-45, wherein step (b) is conducted at least 1 week after step (a).
  • Embodiment 49 is the method of any one of embodiments 23-45, wherein step (b) is conducted at least 2 weeks after step (a).
  • Embodiment 50 is a vaccine combination comprising (a) a first composition comprising an immunologically effective amount of an adenovirus vector comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:4; and (b) a second composition comprising an immunologically effective amount of a Modified Vaccinia Ankara (MV A) vector comprising a second polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO: 4; wherein the first composition is administered to the human subject for priming the immune response, and the second composition is administered to the human subject one or more times for boosting the immune response.
  • MV A Modified Vaccinia Ankara
  • Embodiment 51 is the vaccine combination of embodiment 50, wherein the HBV polymerase antigen of the first and second composition does not have reverse transcriptase activity and RNase H activity.
  • Embodiment 52 is the vaccine combination of embodiment 50 or 51, wherein the HBV polymerase antigen of the first and second composition is capable of inducing an immune response in a mammal against at least two HBV genotypes, preferably the HBV polymerase antigen is capable of inducing a T cell response in a mammal against at least HBV genotypes B, C, and D, and more preferably the HBV polymerase antigen is capable of inducing a CD8 T cell response in a human subject against at least HBV genotypes A, B, C, and D.
  • the HBV polymerase antigen of the first and second composition is capable of inducing an immune response in a mammal against at least two HBV genotypes, preferably the HBV polymerase antigen is capable of inducing a T cell response in a mammal against at least HBV genotypes B, C, and D, and more preferably the HBV polymerase antigen is capable of inducing a CD8 T cell response in
  • Embodiment 53 is the vaccine combination of any one of embodiments 50-52, wherein the HBV polymerase antigen of the first and second composition comprises the amino acid sequence of SEQ ID NO: 4.
  • Embodiment 54 is the vaccine combination of any one of embodiments 50-53, further comprising a polynucleotide sequence encoding a signal sequence operably linked to the HBV polymerase antigen of the first and second composition.
  • Embodiment 55 is the vaccine combination of embodiment 54, wherein the signal sequence comprises the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 11, preferably the signal sequence is encoded by the polynucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 10.
  • Embodiment 56 is the vaccine combination of any one of embodiments 50-55, wherein the first and second polynucleotide sequence is at least 90% identical to SEQ ID NO: 3.
  • Embodiment 57 is the vaccine combination of embodiment 56, wherein the first and second polynucleotide sequence comprises the polynucleotide sequence of SEQ ID NO: 3.
  • Embodiment 58 is the vaccine combination of any one of embodiments 50-57, wherein the adenovirus vector of the first composition further comprises a third polynucleotide sequence and the MVA vector of the second composition further comprises a fourth polynucleotide sequence, wherein the third and fourth polynucleotide sequence encode a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2.
  • Embodiment 59 is the vaccine combination of embodiment 58, wherein the third and fourth polynucleotide sequence is at least 90% identical to SEQ ID NO: 1.
  • Embodiment 60 is the vaccine combination of embodiment 59, wherein the third and fourth polynucleotide sequence comprises the polynucleotide sequence of SEQ ID NO: 1.
  • Embodiment 61 is a vaccine combination comprising (a) a first composition comprising an immunologically effective amount of a Modified Vaccinia Ankara (MV A) vector comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:4; and (b) a second composition comprising an immunologically effective amount of an adenovirus vector comprising a second polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:4; wherein the first composition is administered to the human subject for priming the immune response, and the second composition is administered to the human subject one or more times for boosting the immune response.
  • MV A Modified Vaccinia Ankara
  • Embodiment 62 is the vaccine combination of embodiment 61, wherein the HBV polymerase antigen of the first and second composition does not have reverse transcriptase activity and RNase H activity.
  • Embodiment 63 is the vaccine combination of embodiment 61 or 62, wherein the HBV polymerase antigen of the first and second composition is capable of inducing an immune response in a mammal against at least two HBV genotypes, preferably the HBV polymerase antigen is capable of inducing a T cell response in a mammal against at least HBV genotypes B, C, and D, and more preferably the HBV polymerase antigen is capable of inducing a CD8 T cell response in a human subject against at least HBV genotypes A, B, C, and D.
  • the HBV polymerase antigen of the first and second composition is capable of inducing an immune response in a mammal against at least two HBV genotypes, preferably the HBV polymerase antigen is capable of inducing a T cell response in a mammal against at least HBV genotypes B, C, and D, and more preferably the HBV polymerase antigen is capable of inducing a CD8 T
  • Embodiment 64 is the vaccine combination of any one of embodiments 61-63, wherein the HBV polymerase antigen of the first and second composition comprises the amino acid sequence of SEQ ID NO: 4.
  • Embodiment 65 is the vaccine combination of any one of embodiments 61-64, further comprising a polynucleotide sequence encoding a signal sequence operably linked to the HBV polymerase antigen of the first and second composition.
  • Embodiment 66 is the vaccine combination of embodiment 65, wherein the signal sequence comprises the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 11, preferably the signal sequence is encoded by the polynucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 10.
  • Embodiment 67 is the vaccine combination of any one of embodiments 61-66, wherein the first and second polynucleotide sequence is at least 90% identical to SEQ ID NO: 3.
  • Embodiment 68 is the vaccine combination of embodiment 67, wherein the first and second polynucleotide sequence comprises the polynucleotide sequence of SEQ ID NO: 3.
  • Embodiment 69 is the vaccine combination of any one of embodiments 61-68, wherein the MVA vector of the first composition further comprises a third polynucleotide sequence and the adenovirus vector of the second composition further comprises a fourth polynucleotide sequence, wherein the third and fourth polynucleotide sequence encode a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2.
  • Embodiment 70 is the vaccine combination of embodiment 69, wherein the third and fourth polynucleotide sequence is at least 90% identical to SEQ ID NO: 1.
  • Embodiment 71 is the vaccine combination of embodiment 70, wherein the third and fourth polynucleotide sequence comprises the polynucleotide sequence of SEQ ID NO: 1.
  • Embodiment 72 is the vaccine combination of any one of embodiments 50-71, which is a kit.
  • Embodiment 73 is a method of enhancing an immune response in a human subject, the method comprising (a) administering to the human subject a first composition comprising an immunologically effective amount of a first plasmid comprising a first non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO: 4 and a second plasmid comprising a second non-naturally occurring nucleic acid molecule comprising a second polynucleotide sequence encoding a truncated HBV core antigen consisting of the amino acid sequence of SEQ ID NO: 2; and (b) administering to the human subject a second composition comprising an immunologically effective amount of a first plasmid comprising a first non-naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising
  • Embodiment 74 is the method of embodiment 73, wherein the HBV polymerase antigen of the first composition does not have reverse transcriptase activity and RNase H activity.
  • Embodiment 75 is the method of embodiment 73 or 74, wherein the first composition is for priming the immune response and the second composition is for boosting the immune response.
  • Embodiment 76 is the method of any one of embodiments 73-75, wherein the HBV polymerase antigen of the first composition is capable of inducing an immune response in the human subject against at least two HBV genotypes, preferably the HBV polymerase antigen is capable of inducing a T cell response in the human subject against at least HBV genotypes B, C, and D, and more preferably the HBV polymerase antigen is capable of inducing a CD8 T cell response in the human subject against at least HBV genotypes A, B, C, and D.
  • the HBV polymerase antigen of the first composition is capable of inducing an immune response in the human subject against at least two HBV genotypes, preferably the HBV polymerase antigen is capable of inducing a T cell response in the human subject against at least HBV genotypes B, C, and D, and more preferably the HBV polymerase antigen is capable of inducing a CD8 T cell response in the human subject against at least HBV
  • Embodiment 77 is the method of any one of embodiments 73-76, wherein the HBV polymerase antigen of the first composition comprises the amino acid sequence of SEQ ID NO: 4.
  • Embodiment 78 is the method of any one of embodiments 73-77, further comprising a polynucleotide sequence encoding a signal sequence operably linked to the HBV polymerase antigen of the first composition.
  • Embodiment 79 is the method of embodiment 78, wherein the signal sequence comprises the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 11, preferably the signal sequence is encoded by the polynucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 10.
  • Embodiment 80 is the method of any one of embodiments 73-79, wherein the first polynucleotide sequence of the first composition is at least 90% identical to SEQ ID NO: 20.
  • Embodiment 81 is the method of embodiment 80, wherein the first polynucleotide sequence of the first composition comprises the polynucleotide sequence of SEQ ID NO: 20.
  • Embodiment 82 is the method of embodiments 73-81, wherein the second polynucleotide sequence of the first composition is at least 90% identical to SEQ ID NO: 18.
  • Embodiment 83 is the method of embodiment 82, wherein the second polynucleotide sequence of the first composition comprises the polynucleotide sequence of SEQ ID NO: 18.
  • Embodiment 84 is the method of any one of embodiments 73-83, wherein the first and second polynucleotide sequences of the first composition further comprise a promoter sequence, optionally one or more additional regulatory sequences, preferably the promoter sequence comprises the polynucleotide sequence of SEQ ID NO: 7, and the additional regulatory sequence is selected from the group consisting of an enhancer sequence of SEQ ID NO: 8 or SEQ ID NO: 15, and a polyadenylation signal sequence of SEQ ID NO: 16.
  • Embodiment 85 is the method of any one of claims 73-84, wherein the enhanced immune response comprises an enhanced antibody response against the HBV antigen in the human subject.
  • Embodiment 86 is the method of embodiment 85, wherein the enhanced immune response comprises an enhanced CD8+ T cell response against the HBV antigen in the human subject.
  • Embodiment 87 is the method of embodiment 85 or 86, wherein the enhanced immune response comprises an enhanced CD4+ T cell response against the HBV antigen in the human subject.
  • Embodiment 88 is the method of any one of embodiments 73-87, wherein step (b) is conducted 1-12 weeks after step (a).
  • Embodiment 89 is the method of any one of embodiments 73-87, wherein step (b) is conducted 2-12 weeks after step (a).
  • Embodiment 90 is the method of any one of embodiments 73-87, wherein step (b) is conducted at least 1 week after step (a).
  • Embodiment 91 is the method of any one of embodiments 73-87, wherein step (b) is conducted at least 2 weeks after step (a).
  • Embodiment 92 is a method of enhancing an immune response in a human subject, the method comprising (a) administering to the human subject a first composition comprising an immunologically effective amount of the MVA vector of any one of embodiments 1-21; and (b) administering to the human subject a second composition comprising an immunologically effective amount of a first plasmid comprising a non- naturally occurring nucleic acid molecule comprising a first polynucleotide sequence encoding an HBV polymerase antigen comprising an amino acid sequence that is at least 98% identical to SEQ ID NO: 4 and a second plasmid comprising a non-naturally occurring nucleic acid molecule comprising a second polynucleotide sequence encoding a truncated HBV core antigen consisting of the amino acid sequence of
  • Embodiment 93 is the method of embodiment 92, wherein the HBV polymerase antigen of the second composition does not have reverse transcriptase activity and RNase H activity.
  • Embodiment 94 is the method of embodiment 92 or 93, wherein the first composition is for priming the immune response and the second composition is for boosting the immune response.
  • Embodiment 95 is the method of any one of embodiments 92-94, wherein the HBV polymerase antigen of the second composition is capable of inducing an immune response in the human subject against at least two HBV genotypes, preferably the HBV polymerase antigen is capable of inducing a T cell response in the human subject against at least HBV genotypes B, C, and D, and more preferably the HBV polymerase antigen is capable of inducing a CD8 T cell response in the human subject against at least HBV genotypes A, B, C, and D.
  • the HBV polymerase antigen of the second composition is capable of inducing an immune response in the human subject against at least two HBV genotypes, preferably the HBV polymerase antigen is capable of inducing a T cell response in the human subject against at least HBV genotypes B, C, and D, and more preferably the HBV polymerase antigen is capable of inducing a CD8 T cell response in the human subject against at least HBV genotyp
  • Embodiment 96 is the method of any one of embodiments 92-95, wherein the HBV polymerase antigen of the second composition comprises the amino acid sequence of SEQ ID NO: 4.
  • Embodiment 97 is the method of any one of embodiments 92-96, further comprising a polynucleotide sequence encoding a signal sequence operably linked to the HBV polymerase antigen of the second composition.
  • Embodiment 98 is the method of embodiment 97, wherein the signal sequence comprises the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 11, preferably the signal sequence is encoded by the polynucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 10.
  • Embodiment 99 is the method of any one of embodiments 92-98, wherein the first polynucleotide sequence of the second composition is at least 90% identical to SEQ ID NO: 20.
  • Embodiment 100 is the method of embodiment 99, wherein the first polynucleotide sequence of the second composition comprises the polynucleotide sequence of SEQ ID NO: 20.
  • Embodiment 101 is the method of embodiments 92-100, wherein the second polynucleotide sequence of the second composition is at least 90% identical to SEQ ID NO: 18.
  • Embodiment 102 is the method of embodiment 101, wherein the second polynucleotide sequence of the second composition comprises the polynucleotide sequence of SEQ ID NO: 18.
  • Embodiment 103 is the method of any one of embodiments 92-102, wherein the first and second polynucleotide sequences of the second composition further comprise a promoter sequence, optionally one or more additional regulatory sequences, preferably the promoter sequence comprises the polynucleotide sequence of SEQ ID NO: 7 , and the additional regulatory sequence is selected from the group consisting of an enhancer sequence of SEQ ID NO: 8 or SEQ ID NO: 15, and a polyadenylation signal sequence of SEQ ID NO: 16.
  • Embodiment 104 is the method of any one of claims 92-103, wherein the enhanced immune response comprises an enhanced antibody response against the HBV antigen in the human subject.
  • Embodiment 105 is the method of embodiment 104, wherein the enhanced immune response comprises an enhanced CD8+ T cell response against the HBV antigen in the human subject.
  • Embodiment 106 is the method of embodiment 104 or 105, wherein the enhanced immune response comprises an enhanced CD4+ T cell response against the HBV antigen in the human subject.
  • Embodiment 107 is the method of any one of embodiments 92-106, wherein step (b) is conducted 1-12 weeks after step (a).
  • Embodiment 108 is the method of any one of embodiments 92-106, wherein step (b) is conducted 2-12 weeks after step (a).
  • Embodiment 109 is the method of any one of embodiments 92-106, wherein step (b) is conducted at least 1 week after step (a).
  • Embodiment 110 is the method of any one of embodiments 92-106, wherein step (b) is conducted at least 2 weeks after step (a).
  • Embodiment 111 is the method of any one of embodiments 92-106, wherein step (b) is conducted at least 4 weeks after step (a).
  • Embodiment 112 is the method of any one of embodiments 92-106, wherein step (b) is conducted at least 8 weeks after step (a).
  • Embodiment 113 is the method of any one of embodiments 92-106, wherein step (b) is conducted at least 12 weeks after step (a).
  • T-cell epitopes on the hepatitis core protein are considered important for elimination of hepatitis B infection and hepatitis B viral proteins, such as polymerase, may serve to improve the breadth of the response.
  • hepatitis B core and polymerase proteins were selected as antigens for the design of a therapeutic hepatitis B virus (HBV) vaccine.
  • HBV pol and core antigen consensus sequences were generated based on HBV genotypes B, C, and D. Different HBV sequences were obtained from different sources and aligned separately for core and polymerase proteins. Original sequence alignments for all subtypes (A to H) were subsequently limited to HBV genotypes, B, C, and D. Consensus sequences were defined for each protein alignment in each subtype separately and in all joint BCD sequences. In variable alignment positions, the most frequent amino acid was used in the consensus sequence.
  • the HBV core antigen consensus sequence was optimized by making two deletions contained in the native viral protein.
  • the first deletion was a deletion of the N- terminal extension of the core protein constituting the pre-core“zinc finger” portion, because reports in the literature have indicated that the virus utilizes this sequence to induce tolerance to viral proteins in infected individuals.
  • the second deletion was a deletion of thirty-four amino acids corresponding to the C-terminal highly positively charged segment, which is required for pre-genome encapsidation and productive viral positive-strand DNA synthesis in the viral life-cycle.
  • the HBV pol antigen consensus sequence was optimized by changing four residues to remove reverse transcriptase and RNAseH enzymatic activities.
  • the aspartate residues (D) were changed to asparagine residues (N) in the“YXDD” motif of the reverse transcriptase domain to eliminate any coordination function, and thus nucleotide/metal ion binding.
  • the first aspartate residue (D) was changed to an asparagine residue (N) and the first glutamate residue (E) was changed to a glutamine residue (A) in the“DEDD” motif of the RNAseH domain to eliminate Mg2+
  • HBV pol antigen was codon optimized to scramble the internal open reading frames for the envelope proteins, including the S protein and versions of the S protein with the N-terminal extensions pre-Sl and pre-S2.
  • Example 2 Generation of Adenoviral Vectors Expressing a Fusion of Truncated HBV Core Antigen with HBV Pol Antigen
  • An adenovirus vector was created to express a fusion protein of a truncated HBV core antigen and a HBV pol antigen from a single open reading frame. Additional configurations for the expression of the two proteins (e.g., the truncated HBV core antigen and the HBV pol antigen), e.g. using two separate expression cassettes, or using a 2A-like sequence to separate the two sequences, can also be envisaged.
  • the expression cassettes (diagrammed in Fig. 2A and Fig. 2B) comprise the CMV promoter (SEQ ID NO:7), an intron (SEQ ID NO: 15) (a fragment derived from the human ApoAI gene - GenBank accession X01038 base pairs 295 - 523, harboring the ApoAI second intron), followed by the optimized coding sequence - either core alone or the core and polymerase fusion protein preceded by a human immunoglobulin secretion signal coding sequence (SEQ ID NO: 10), and followed by the SV40 polyadenylation signal (SEQ ID NO: 16).
  • a secretion signal was included because of past experience showing improvement in the manufacturability of some adenoviral vectors harboring secreted transgenes, without influencing the elicited T-cell response (mouse experiments).
  • An MVA vector has been designed to encode each of the HBV Core and Pol coding sequences of the application.
  • Each of the HBV Core and Pol coding sequences were inserted into an MVA vector at IGR44/45, each under the control of a separate promoter.
  • Additional configurations for the expression of the two proteins e.g. using a single expression cassette wherein the Core and Pol antigen comprise a fusion protein, or alternatively utilizing a 2A-like sequence to separate the two sequences, can also be envisaged.
  • additional and/or alternative insertions sites in the MVA vector can also be envisaged, e.g., inserting each of the HBV Core and Pol coding sequences into the same or different insertion sites.
  • the expression cassettes are comprised of the Prl3.5long promoter (SEQ ID NO: 25) adjacent to and directing expression of the HBV Core antigen and the PrHyb promoter (SEQ ID NO: 26) adjacent to and directing expression of the HBV Pol antigen.
  • the HBV core coding sequence comprises SEQ ID NO: 1 and the HBV Pol coding sequence comprises SEQ ID NO: 3.
  • Each of SEQ ID NOs: 1 and 3 were modified by eliminating negative cis-acting sites and by adjusting the GC content.
  • each of SEQ ID NOs: 1 and 3 were codon optimized for human codon usage without affecting the amino acid sequence.
  • Each of SEQ ID NOs: 1 and 3 comprises an additional early termination signals (TTTTTNT (SEQ ID NO: 28)) arranged adjacent to the stop codon.
  • Example 4 Immunogenicity of combinations of HBV adenoviral vectors and HBV MVA vectors in mice
  • Vector design Two adenoviral vectors expressing either Core alone (an HBV core antigen having the amino acid sequence of SEQ ID NO: 2), or Polymerase (an HBV pol antigen having the amino acid sequence of SEQ ID NO: 4) in addition to Core as a fusion protein expressed from a single open reading frame were used. For this, sequences were designed in silico to provide a consensus for the B, C and D genotypes of the hepatitis B virus.
  • the expression cassettes comprise the CMV promoter, an ApoAI intron, a human immunoglobulin secretion signal, followed by the coding sequence - either Core alone or the Core and Polymerase fusion protein and a SV40 polyadenylation signal.
  • the recombinant MVA vector is comprised of poxvirus promoter Prl3.5 (SEQ ID NO:25) linked to the core coding sequence (nucleotide sequence of SEQ ID NO: 1 , and polypeptide sequence of SEQ ID NO:2) and PrHyb (SEQ ID NO: 26) linked to a nucleotide sequence encoding for polymerase (nucleotide sequence of SEQ ID NO: 3, and polypeptide sequence of SEQ ID NO: 4), both followed by a transcription termination sequence of TTTTTNT (SEQ ID NO: 28).
  • the core coding sequence comprises an N-terminal immunoglobulin secretion tag (SEQ ID NO: 11), and the polymerase coding sequence comprises an N-terminal cystatin S signal sequence (SEQ ID NO: 6). See, e g., FIG. 2C.
  • Antigen-specific responses were analyzed and quantified by IFN-g enzyme- linked immunospot (ELISPOT) and intracellular cytokine production (TNF-alpha, IL-2 and IFN-g) was detected by flow cytometry.
  • IFN-g enzyme- linked immunospot ELISPOT
  • TNF-alpha, IL-2 and IFN-g intracellular cytokine production
  • the large 94 kDa HBV Pol protein was split in the middle into two peptide pools.
  • ELISPOT IFN-g release by a single antigen- specific T-cell was visualized by appropriate antibodies and subsequent chromogenic detection as a colored spot on the microplate referred to as spot-forming cell (SFC).
  • SFC spot-forming cell
  • ICS the percentage of cytokine-releasing cells in a particular population (CD3 -positive, CD4-positive or CD8-positive cells) was determined.
  • IM intramuscular
  • vp viral preceded es
  • TCID50 50% tissue culture infective dose
  • MVA 50% tissue culture infective dose
  • HBV adenoviral vectors alone and in combination with HBV MVA vector gave rise to Pol specificT cell responses in mice.
  • Low-level core responses were induced by Core pol fusion + core adenoviral vectors and these responses where amplified by boosting with HBV MVA vector.
  • HBV MVA vector also induced core responses (FIG. 3).
  • Pol responses are primarily mediated by CD8(+) T cells, whereas Core responses primarily involve CD4(+) T cells (FIGS. 4 and 5).
  • the combination of Core pol fusion + core adenovectors and HBV MVA also induced CD8(+) T cell driven core responses (FIG. 4).
  • HBV adenoviral vectors and HBV MVA vectors
  • Mauritian cynomolgus monkeys were prime-boost-boost immunized intramuscularly with different vector combinations. These immunogenicity studies focused on determining the cellular immune responses elicited by the HBV core and polymerase antigens.
  • Antigen-specific responses were analyzed and quantified by IFN-g enzyme- linked immunospot (ELISPOT) and intracellular cytokine production (TNF-alpha, IL-2 and IFN-g) was detected by flow cytometry.
  • ELISPOT enzyme- linked immunospot
  • TNF-alpha, IL-2 and IFN-g intracellular cytokine production
  • flow cytometry PBMCs of immunized animals were incubated with peptide pools covering the Core protein or the Pol protein (2pg/ml of each peptide).
  • the pools consist of l5-mer peptides that overlap by 11 residues matching the genotypes ABCD consensus sequence of the Core and Pol adenoviral vectors.
  • the large 94 kDa HBV Pol protein was split in the middle into two peptide pools.
  • ELISPOT IFN-g release by a single antigen-specific T-cell was visualized by appropriate antibodies and subsequent chromogenic detection as a colored spot on the microplate referred to as spot-forming cell (SFC).
  • SFC spot-forming cell
  • ICS intracellular cytokine staining
  • IM intramuscular
  • vp viral particles
  • TCID50 50% tissue culture infective dose
  • MVA Modified Vaccinia Ankara
  • Core and Pol responses in NHPs are mediated by both CD4(+) and CD8(+) T cells.
  • the combination of Core pol fusion adenovectors + core adenovectors (used as a prime) and HBV MVA (used as a boost) induced the highest CD4(+) Core specific and CD8(+) Pol specific T cell IFN-g responses (FIG. 7).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PCT/IB2018/060257 2017-12-19 2018-12-18 Methods and compositions for inducing an immune response against hepatitis b virus (hbv) WO2019123250A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2018389786A AU2018389786A1 (en) 2017-12-19 2018-12-18 Methods and compositions for inducing an immune response against hepatitis B virus (HBV)
BR112020012273-4A BR112020012273A2 (pt) 2017-12-19 2018-12-18 métodos e composições para induzir uma resposta imune contra o vírus da hepatite b (hbv)
EA202091516A EA202091516A1 (ru) 2017-12-19 2018-12-18 Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
CA3086325A CA3086325A1 (en) 2017-12-19 2018-12-18 Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
MX2020006471A MX2020006471A (es) 2017-12-19 2018-12-18 Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
SG11202005710YA SG11202005710YA (en) 2017-12-19 2018-12-18 Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
JP2020533786A JP2021506300A (ja) 2017-12-19 2018-12-18 Ｂ型肝炎ウイルス（ｈｂｖ）に対する免疫応答を誘導するための方法および組成物
CN201880089584.0A CN111741766A (zh) 2017-12-19 2018-12-18 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物
EP18839618.8A EP3727446A1 (en) 2017-12-19 2018-12-18 Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
KR1020207020749A KR20200100745A (ko) 2017-12-19 2018-12-18 B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물
IL275423A IL275423A (en) 2017-12-19 2020-06-16 Methods and preparations for inducing an immune response against hepatitis virus HBV) B)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762607439P 2017-12-19 2017-12-19
IB2017058148 2017-12-19
IBPCT/IB2017/058148 2017-12-19
US62/607,439 2017-12-19

Publications (1)

Publication Number Publication Date
WO2019123250A1 true WO2019123250A1 (en) 2019-06-27

Family

ID=65201641

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/060257 WO2019123250A1 (en) 2017-12-19 2018-12-18 Methods and compositions for inducing an immune response against hepatitis b virus (hbv)

Country Status (12)

Country Link
EP (1) EP3727446A1 (ja)
JP (1) JP2021506300A (ja)
KR (1) KR20200100745A (ja)
CN (1) CN111741766A (ja)
AU (1) AU2018389786A1 (ja)
BR (1) BR112020012273A2 (ja)
CA (1) CA3086325A1 (ja)
IL (1) IL275423A (ja)
MA (1) MA51312A (ja)
MX (1) MX2020006471A (ja)
SG (1) SG11202005710YA (ja)
WO (1) WO2019123250A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020255055A1 (en) * 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines

Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (en) 1904-11-07 1905-03-14 William Waid Paddock Pressure filter
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6110161A (en) 1997-04-03 2000-08-29 Electrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
WO2000070071A1 (en) 1999-05-17 2000-11-23 Crucell Holland B.V. Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
WO2002024224A2 (en) 2000-09-21 2002-03-28 Oxxon Pharmaccines Limited Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen
WO2002042480A2 (en) 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant
WO2003048184A2 (en) 2001-12-04 2003-06-12 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
WO2004001032A2 (en) 2002-04-25 2003-12-31 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
US6697669B2 (en) 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
WO2005071093A2 (en) 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Chimpanzee adenovirus vaccine carriers
US6939862B2 (en) 1997-06-30 2005-09-06 Aventis Pharma S.A. Method for transferring nucleic acid into striated muscles
US7270811B2 (en) 1999-05-18 2007-09-18 Crucell Holland B.V. Serotype of adenovirus and uses thereof
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US7664545B2 (en) 2002-03-07 2010-02-16 Vgx Pharmaceuticals, Inc. Electrode assembly for constant-current electroporation and use
WO2010060632A1 (en) 2008-11-27 2010-06-03 Bavarian Nordic A/S Promoters for recombinant viral expression
WO2010086189A2 (en) 2009-02-02 2010-08-05 Okairòs Ag, Switzerland Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010102822A1 (en) 2009-03-13 2010-09-16 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines
WO2011015656A2 (en) * 2009-08-07 2011-02-10 Transgene Sa Composition for treating hbv infection
US20110110974A1 (en) * 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
WO2012082918A1 (en) 2010-12-14 2012-06-21 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Adenovirus serotype 26 and serotype 35 filovirus vaccines
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
WO2013189611A1 (en) 2012-06-22 2013-12-27 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
WO2014063832A1 (en) 2012-10-28 2014-05-01 Bavarian Nordig A/S Pr13.5 promoter for robust t-cell and antibody responses
US9364664B2 (en) 2004-03-08 2016-06-14 Ichor Medical Systems, Inc. Apparatus for electrically mediated delivery of therapeutic agents
US9452285B2 (en) 2006-10-17 2016-09-27 Vgx Pharmaceuticals, Inc. Electroporation devices and methods of using same for electroporation of cells in mammals
WO2017021776A1 (en) 2015-07-31 2017-02-09 Bavarian Nordic A/S Promoters for enhancing expression in poxviruses
WO2017172838A1 (en) 2016-03-28 2017-10-05 Ichor Medical Systems, Inc. Method and apparatus for delivery of therapeutic agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248173A (zh) * 2005-04-08 2008-08-20 墨尔本保健公司 对于抗病毒核苷试剂具有抗性的乙型肝炎病毒变异体及其应用
SI3402888T1 (sl) * 2016-01-12 2021-02-26 Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Sredstva in metode za zdravljenje HBV

Patent Citations (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (en) 1904-11-07 1905-03-14 William Waid Paddock Pressure filter
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US6958060B2 (en) 1997-04-03 2005-10-25 Genetronics, Inc. Method for muscle delivery of drugs, nucleic acids and other compounds
US6110161A (en) 1997-04-03 2000-08-29 Electrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6278895B1 (en) 1997-04-24 2001-08-21 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
US6939862B2 (en) 1997-06-30 2005-09-06 Aventis Pharma S.A. Method for transferring nucleic acid into striated muscles
US6697669B2 (en) 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
WO2000070071A1 (en) 1999-05-17 2000-11-23 Crucell Holland B.V. Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
US7270811B2 (en) 1999-05-18 2007-09-18 Crucell Holland B.V. Serotype of adenovirus and uses thereof
WO2002024224A2 (en) 2000-09-21 2002-03-28 Oxxon Pharmaccines Limited Use of replication-deficient poxvirus vector to boost cd4+ t cell immune response to antigen
US6761893B2 (en) 2000-11-23 2004-07-13 Bavarian Nordic A/S Modified vaccinia ankara virus variant
US20030206926A1 (en) 2000-11-23 2003-11-06 Paul Chaplin Modified vaccinia ankara virus variant
WO2002042480A2 (en) 2000-11-23 2002-05-30 Bavarian Nordic A/S Modified vaccinia ankara virus variant
WO2003048184A2 (en) 2001-12-04 2003-06-12 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
US20060159699A1 (en) 2001-12-04 2006-07-20 Paul Howley Flavivirus ns1 subunit vaccine
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7664545B2 (en) 2002-03-07 2010-02-16 Vgx Pharmaceuticals, Inc. Electrode assembly for constant-current electroporation and use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US8187249B2 (en) 2002-04-05 2012-05-29 Ichor Medical Systems, Inc. Method and apparatus for delivery of therapeutic agents
WO2004001032A2 (en) 2002-04-25 2003-12-31 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
WO2005071093A2 (en) 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Chimpanzee adenovirus vaccine carriers
US9802035B2 (en) 2004-03-08 2017-10-31 Ichor Medical Systems, Inc. Apparatus for electrically mediated delivery of therapeutic agents
US9364664B2 (en) 2004-03-08 2016-06-14 Ichor Medical Systems, Inc. Apparatus for electrically mediated delivery of therapeutic agents
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
US9452285B2 (en) 2006-10-17 2016-09-27 Vgx Pharmaceuticals, Inc. Electroporation devices and methods of using same for electroporation of cells in mammals
US20110110974A1 (en) * 2007-10-29 2011-05-12 Erik Depla Methods and kits for inducing a ctl response using a prime boost regimen
WO2010060632A1 (en) 2008-11-27 2010-06-03 Bavarian Nordic A/S Promoters for recombinant viral expression
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010086189A2 (en) 2009-02-02 2010-08-05 Okairòs Ag, Switzerland Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2010102822A1 (en) 2009-03-13 2010-09-16 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines
WO2011015656A2 (en) * 2009-08-07 2011-02-10 Transgene Sa Composition for treating hbv infection
WO2012082918A1 (en) 2010-12-14 2012-06-21 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Adenovirus serotype 26 and serotype 35 filovirus vaccines
WO2013189611A1 (en) 2012-06-22 2013-12-27 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
WO2014063832A1 (en) 2012-10-28 2014-05-01 Bavarian Nordig A/S Pr13.5 promoter for robust t-cell and antibody responses
WO2017021776A1 (en) 2015-07-31 2017-02-09 Bavarian Nordic A/S Promoters for enhancing expression in poxviruses
WO2017172838A1 (en) 2016-03-28 2017-10-05 Ichor Medical Systems, Inc. Method and apparatus for delivery of therapeutic agents

Non-Patent Citations (38)

* Cited by examiner, † Cited by third party
Title
"generally, Current Protocols in Molecular Biology", 1995, GREENE PUBLISHING ASSOCIATES, INC. AND JOHN WILEY & SONS, INC.
"Molecular Biology", 1998, JOHN WILEY & SON, INC.
"Molecular Cloning, A laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
"The Practical Approach Series", 1993, IRL PRESS
"Virology Methods Manual", 1996, ACADEMIC PRESS
ABBINK ET AL., VIROL, vol. 81, no. 9, 2007, pages 4654 - 63
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
BANGARI; MITTAL, VACCINE, vol. 24, 2006, pages 849 - 62
BELLONI ET AL.: "IFN-a inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome", J. CLIN. INVEST., vol. 122, no. 2, 2012, pages 529 - 537, XP055272832, DOI: doi:10.1172/JCI58847
BOUKAMP ET AL., J. CELL BIOL, vol. 106, 1988, pages 761 - 771
COHEN ET AL., J GEN VIROL, vol. 83, 2002, pages 151 - 55
COHEN ET AL.: "Is chronic hepatitis B being undertreated in the United States", J. VIRAL HEPAT, vol. 18, no. 6, 2011, pages 377 - 83
COLIGAN ET AL.: "Current Protocols in Immunology", 1992, J WILEY & SONS INC
FARINA ET AL., J VIROL, vol. 75, 2001, pages 11603 - 13
HARLOW: "Antibodies", 1989, COLD SPRING HARBOR PRESS
HAVENGA ET AL., J GEN VIROL, vol. 87, 2006, pages 2135 - 43
HENIKOFF; HENIKOFF, PROC. NATL. ACAD. SCI., vol. 89, 1989, pages 10915
KARLIN; ALTSCHUL, PROC. NAT'L. ACAD. SCI., vol. 90, 1993, pages 5873 - 5787
KOBINGER ET AL., VIROLOGY, vol. 346, 2006, pages 394 - 401
LASARO; ERTL, MOL THER, vol. 17, 2009, pages 1333 - 39
MAYR, A. ET AL., INFECTION, vol. 3, 1975, pages 6 - 14
MAYR, A.; DANNER, K., DEV. BIOL. STAND., vol. 41, 1978, pages 225 - 34
MEYER, H. ET AL., J. GEN. VIROL., vol. 72, 1991, pages 1031 - 1038
MICHEL ET AL.: "Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges", J. HEPATOL., vol. 54, no. 6, 2011, pages 1286 - 1296, XP028210472, DOI: doi:10.1016/j.jhep.2010.12.031
NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443
OBENG-ADJEI ET AL.: "DNA vaccine cocktail expressing genotype A and C HBV surface and consensus core antigens generates robust cytotoxic and antibody responses and mice and Rhesus macaques", CANCER GENE THERAPY, vol. 20, 2013, pages 652 - 662, XP055259543, DOI: doi:10.1038/cgt.2013.65
PEARSON; LIPMAN, PROC. NAT'L. ACAD. SCI., vol. 85, 1988, pages 2444
PERRINE MARTIN ET AL: "TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice", GUT, vol. 64, no. 12, 26 November 2014 (2014-11-26), UK, pages 1961 - 1971, XP055453477, ISSN: 0017-5749, DOI: 10.1136/gutjnl-2014-308041 *
RALF BARTENSCHLAGER ET AL: "Expression of the P-protein of the human hepatitis B virus in a vaccinia virus system and detection of the nucleocapsid-associated P-gene product by radiolabelling at newly introduced phosphorylation sites", NUCLEIC ACIDS RESEARCH, vol. 20, no. 2, 1 January 1992 (1992-01-01), pages 195 - 202, XP055454054, ISSN: 0305-1048, DOI: 10.1093/nar/20.2.195 *
RAMIREZ JUAN C ET AL: "Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: Virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 2, 1 January 2000 (2000-01-01), pages 923 - 933, XP002292277, ISSN: 0022-538X, DOI: 10.1128/JVI.74.2.923-933.2000 *
REYES-SANDOVAL ARTURO ET AL: "Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8(+) T-Cell Responses", INFECTION AND IMMUNITY, vol. 78, no. 1, January 2010 (2010-01-01), pages 145 - 153, XP002778539 *
SAMBROOK ET AL.: "Molecular Cloning a Laboratory Manual", 1989, COLD SPRING HARBOR PRESS
SMITH; WATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482
SUTER ET AL., VACCINE, 2009
TATSIS ET AL., MOLECULAR THERAPY, vol. 15, 2007, pages 608 - 17
VOGELS ET AL., J VIROL, vol. 77, no. 15, 2003, pages 8263 - 71
WORLD HEALTH ORGANIZATION, HEPATITIS B, March 2015 (2015-03-01), Retrieved from the Internet <URL:http://www.who.nt/mediacentre/factsheets/fs204/en/>

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
US11725194B2 (en) 2017-12-19 2023-08-15 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
WO2020255055A1 (en) * 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof

Also Published As

Publication number Publication date
EP3727446A1 (en) 2020-10-28
KR20200100745A (ko) 2020-08-26
MA51312A (fr) 2020-10-28
MX2020006471A (es) 2020-09-22
JP2021506300A (ja) 2021-02-22
CA3086325A1 (en) 2019-06-27
SG11202005710YA (en) 2020-07-29
BR112020012273A2 (pt) 2020-11-24
CN111741766A (zh) 2020-10-02
IL275423A (en) 2020-08-31
AU2018389786A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
US11020476B2 (en) Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
US11725194B2 (en) Hepatitis B virus (HBV) vaccines and uses thereof
US10912827B2 (en) Means and methods for treating HBV
EP3727445B1 (en) Hepatitis b virus (hbv) vaccines and uses thereof
WO2019123250A1 (en) Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
US20220305116A1 (en) Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
WO2020255013A1 (en) Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
US20220233526A1 (en) Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
US20220226467A1 (en) Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
US20220249647A1 (en) Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2020255021A1 (en) Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor
WO2020255010A1 (en) Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
WO2020254876A1 (en) Virus-like particle delivery of hepatitis b virus (hbv) vaccines
US20220324916A1 (en) Hepatitis B Virus (HBV) Vaccines and Uses Thereof
TW201928061A (zh) 誘發抗b型肝炎病毒(hbv)免疫反應之方法及組合物
OA19833A (en) Hepatitis B virus (HBV) vaccines and uses thereof.
WO2020255035A1 (en) Combination of hepatitis b virus (hbv) vaccines and pyrimidine derivatives
EA045279B1 (ru) Вакцины против вируса гепатита b (hbv) и их применение

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18839618

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018389786

Country of ref document: AU

Date of ref document: 20181218

Kind code of ref document: A

Ref document number: 3086325

Country of ref document: CA

Ref document number: 2020533786

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20207020749

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018839618

Country of ref document: EP

Effective date: 20200720

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020012273

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020012273

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200617